Blood Pressure

A specifically designed 12-week randomized clinical trial in adults with metabolic syndrome found that 20 g/day of acacia gum significantly reduced both systolic (p=0.008) and diastolic (p=0.009) blood pressure compared to placebo. This finding has not been universally replicated and may relate to the broader metabolic improvements produced by gum arabic.

ALC has been shown to reduce systolic blood pressure in insulin-resistant, non-diabetic subjects at high cardiovascular risk in a clinical pilot RCT. This effect appears linked to improvement in insulin sensitivity and increased adiponectin levels, which in turn raise nitric oxide and promote vasodilation. A larger RCT in type 2 diabetic patients on statin therapy, however, did not confirm a blood pressure-lowering effect, indicating context-dependence.

Adzuki bean extracts significantly reduced systolic blood pressure and ACE activity in spontaneously hypertensive rats across multiple animal studies. Polyphenol-containing seed coat extracts also attenuated vascular oxidative stress. No published human RCT has used blood pressure as a primary endpoint for adzuki bean.

A PubMed-indexed study (Gilani et al., related to thymol from T. ammi) characterized calcium channel-blocking hypotensive effects in in vivo and in vitro models. A human RCT (n=99 hypertensive patients) assessed ajwain as an adjunct to antihypertensive therapy, finding within-group HRV improvements. Animal and mechanistic evidence is robust.

Human epidemiological studies show an inverse correlation between A. muciniphila gut abundance and hypertension. Multiple preclinical and observational studies have highlighted a positive role of A. muciniphila in lowering or controlling blood pressure, though the relationship is complex and some studies show conflicting signals. Direct RCT evidence for blood pressure as a primary endpoint in humans is not yet available.

Multiple RCTs and meta-analyses demonstrate ALA modestly reduces systolic blood pressure. Mechanisms include stimulation of nitric oxide production and improved endothelium-dependent vasodilation. Effects on diastolic blood pressure are less consistent.

A 2023 GRADE-assessed systematic review and dose-response meta-analysis of 11 RCTs (n=674) found ALA supplementation significantly reduced both systolic (−5.46 mmHg) and diastolic (−3.36 mmHg) blood pressure. Effects were significant at doses below 800 mg/day administered for up to 12 weeks.

DHA from algal oil has been shown to lower ambulatory blood pressure and heart rate in clinical studies. A dose-response meta-analysis incorporating algal oil trials found that omega-3 PUFAs significantly lower both systolic and diastolic blood pressure. DHA activates large-conductance K+ channels in vascular smooth muscle, causing vasodilation as a proposed mechanism.

Allicin is the primary bioactive compound in garlic responsible for antihypertensive effects. It promotes nitric oxide production, inhibits ACE, and dilates blood vessels. Clinical evidence supporting garlic preparations' blood pressure effects is substantially attributed to allicin content.

Alliin is the precursor to allicin in garlic, converted by alliinase upon garlic cell disruption. The antihypertensive potential of garlic preparations is directly linked to alliin content and subsequent allicin generation. Clinical evidence is derived from studies on allicin-yielding garlic preparations.

Aqueous and ethanolic extracts of Pimenta dioica have demonstrated significant hypotensive activity in anesthetized normotensive rats in a published dose-response study. Polyphenol-based reviews list hypotensive activity among confirmed biological properties. The mechanism involves CNS depression and possible vasorelaxation rather than adrenergic or cholinergic blockade.

Almond consumption is associated with modest but statistically significant reductions in diastolic blood pressure, particularly at doses greater than 42.5 g/day or intervention durations beyond six weeks. Effects on systolic blood pressure are inconsistent across meta-analyses.

Isoquercitrin and its parent compound quercetin have documented hypotensive effects in animal models and are listed among AGIQ's established biological activities. However, the only human RCT of AGIQ (British Journal of Nutrition, 2019) found no significant change in blood pressure after acute AGIQ administration, even as endothelial function improved. Evidence for blood pressure lowering by AGIQ specifically in humans is currently negative or inconclusive.

Amaranth proteins yield ACE-inhibitory peptides upon digestion that have demonstrated blood pressure-lowering effects in hypertensive animal models and in preliminary human data. The antihypertensive effect reaches a level comparable to captopril in animal studies. Human studies, while small, report modest reductions in systolic and diastolic blood pressure.

EPA and DHA from anchovies lower blood pressure through vasodilatory and anti-inflammatory mechanisms. A meta-analysis published in the American Journal of Hypertension confirmed that EPA+DHA provision reduces systolic blood pressure, with doses ≥2 g/day also reducing diastolic blood pressure. Potassium in anchovies additionally supports vasodilation.

Andrographis paniculata contains andrographolide and related diterpenes with evidence for blood pressure reduction in preclinical and some clinical studies. A crude extract containing 14-deoxy-11,12-didehydroandrographolide significantly lowers blood pressure through calcium channel blockade and ACE inhibition.

An RCT in 82 metabolic syndrome patients found that delta-tocotrienol from annatto combined with resveratrol reduced systolic blood pressure by 5.2% and diastolic blood pressure by 5.8% over 24 weeks. Animal data show annatto tocotrienols significantly reduce blood pressure in high-fat/high-cholesterol diet-induced hypertensive rodents. Traditional use of annatto as a hypotensive agent is documented in Peruvian herbal medicine.

Quercetin from apples has demonstrated clinically meaningful blood pressure reductions in hypertensive individuals in RCTs. Apple polyphenol extracts also show endothelium-dependent blood pressure effects through increased nitric oxide bioavailability.

Limited human clinical evidence suggests ACV may produce modest reductions in blood pressure, primarily via acetic acid's proposed effects on the renin-angiotensin system. A 2022 systematic review found controversial results. Most supportive data comes from animal studies; human RCT evidence is weak and inconsistent.

Apricots are a meaningful dietary source of potassium, which is well-established to reduce systolic blood pressure in hypertensive individuals. Dried apricots in particular are among the richest fruit sources of potassium. The anti-inflammatory polyphenols in apricots may also contribute to vascular health. Evidence is primarily from potassium intervention studies and nutritional epidemiology.

L-arginine, the primary component of AAKG, is an established precursor for vascular NO, and meta-analyses of L-arginine RCTs report modest blood-pressure-lowering effects. AAKG-specific BP data are sparse; studies show plasma arginine rises substantially with AAKG but independent BP reduction beyond exercise effects has not been isolated.

Terminalia arjuna bark has centuries of use in Ayurveda for hypertension and cardiovascular disease. Multiple clinical studies, including a 2025 double-blind RCT, confirmed significant SBP and DBP reduction with 1,000 mg/day supplementation in hypertensive geriatric patients. Active glycosides and flavonoids exert diuretic and hypotensive effects.

A meta-analysis of controlled clinical trials (n=327) demonstrated that daily supplementation with Aronia berry extracts for 6–8 weeks significantly reduces systolic blood pressure, particularly in adults over 50. Multiple individual trials in metabolic syndrome patients also report significant antihypertensive effects. The mechanism likely involves ACE inhibition and endothelial antioxidant protection.

A 2025 meta-analysis of multiple RCTs found artichoke supplementation significantly reduced systolic BP (WMD −2.49 mmHg) and diastolic BP (WMD −1.53 mmHg). An earlier meta-analysis of 8 RCTs (n=512) also evaluated blood pressure specifically. Mechanistically, chlorogenic and caffeoylquinic acids exhibit vasodilatory and ACE-inhibitory properties.

Ashitaba's chalcone 4-HD demonstrated hypotensive action in stroke-prone spontaneously hypertensive rats, reducing blood pressure alongside lipid regulation. The plant is also listed in traditional Japanese use for high blood pressure. Preclinical evidence supports antihypertensive activity, but no human RCTs exist.

Clinical studies show modest but statistically significant reductions in both systolic and diastolic blood pressure in stress-related or overweight populations. A 2012 study in 51 stressed adults showed approximately 5 mmHg systolic and 3 mmHg diastolic reduction after 60 days. Mechanisms include cortisol reduction, vasodilation via nitric oxide modulation, and anti-inflammatory effects on the vascular endothelium.

Asparagus officinalis demonstrates antihypertensive activity in animal models via ACE-inhibitory compounds and diuretic effects attributed to asparagine and potassium. A small open human clinical trial (n=28) showed significant reductions in both systolic and diastolic blood pressure after 10 weeks of powdered asparagus intake. Formal pharmacological assessment found asparagus-based preparations inferior to first-line antihypertensives.

Human evidence is mixed: meta-analyses of 5 RCTs found no statistically significant effect on systolic or diastolic blood pressure overall, yet a 2025 cardiovascular review noted human trials suggest positive effects on blood pressure control, particularly through improved endothelial function. Animal data is more robust, showing significant SBP reductions in spontaneously hypertensive rats.

Astragalus polysaccharides (APS) significantly reduced blood pressure in animal hypertension models via TGF-β1/ILK pathway inhibition. In a clinical RCT (n=118) of diabetic CKD patients, add-on astragalus lowered systolic blood pressure by 7.9 mmHg versus standard care (p=0.003). Vasodilation occurs via nitric oxide–cGMP pathway activation.

A randomized, double-blind, placebo-controlled trial in 11 hypertensive older women found that a single 400 mg oral ATP disodium dose reduced systolic blood pressure and accelerated heart rate variability recovery after aerobic exercise. The mechanism involves ATP-induced endothelial vasodilation reducing peripheral vascular resistance. Evidence is currently limited to this small trial in a specific population.

Bamboo shoot peptides (BSP) inhibit ACE (angiotensin-converting enzyme) activity and reduce systolic blood pressure in spontaneously hypertensive rats. Phenolic compounds (ferulic acid, p-coumaric acid) in bamboo contribute synergistic antihypertensive effects. Bamboo shoots are used in TCM for cardiovascular and heat conditions.

A randomized, double-blind, placebo-controlled trial in patients with metabolic syndrome found banaba supplementation significantly reduced systolic blood pressure. Corosolic acid has shown antihypertensive effects in metabolic-syndrome rat models. The antihypertensive mechanism is not fully elucidated but may involve antioxidative and anti-inflammatory pathways.

Banana is one of the most evidence-supported dietary sources of potassium for blood pressure reduction. The SSaSS cohort study (n=20,995, 5 years) linked increased potassium intake to significant reductions in blood pressure and cardiovascular events. Potassium from banana inhibits renin-angiotensin-aldosterone activity and reduces sodium reabsorption.

Clinical trial data show that barberry juice (200 mL/day) significantly improved systolic and diastolic blood pressure in T2DM patients. An RCT in 60 metabolic syndrome patients found a significant decrease in systolic blood pressure after 3 weeks of barberry supplementation. Berberine's antihypertensive mechanism involves vasodilation and reduction of peripheral resistance.

Whole grain barley consumption has been associated with modest reductions in blood pressure, particularly in hypercholesterolemic individuals. Barley β-glucan is documented to reduce cardiovascular risk factors including systolic and diastolic blood pressure in clinical settings.

Eugenol in basil essential oil blocks calcium channels, providing a pharmacological mechanism for blood pressure reduction. The 2017 systematic review of 24 holy basil clinical trials found improvements in blood pressure. A clinical study in cardiovascular patients found basil seeds reduced systolic blood pressure. Ethnobotanical literature also documents use of Ocimum species globally for hypertension.

Bee pollen peptides and polyphenols are proposed to inhibit ACE and support antihypertensive pathways. An in vitro study on cardiovascular-disease microbiota found fermented bee pollen elevated lactic and acetic acids — both with known antihypertensive effects. Traditional use for hypertension is also documented.

Beetroot juice is one of the best-studied natural sources of inorganic nitrate, which is converted to nitric oxide in vivo, significantly reducing blood pressure. The 2015 landmark RCT (Kapil et al., Hypertension) showed beetroot juice reduced SBP by ~8 mmHg in hypertensive patients over 4 weeks. Multiple authoritative nutraceutical reviews cite beetroot juice for BP.

Berberine, an isoquinoline alkaloid from Traditional Chinese Medicine plants, has multiple systematic reviews and meta-analyses supporting blood pressure reduction. It activates AMPK, improves endothelial function, and modulates the renin-angiotensin system. A 2015 meta-analysis confirmed antihypertensive effects alongside lipid and glucose improvements.

Multiple clinical studies and a systematic review and meta-analysis of RCTs indicate that beta-glucan consumption for ≥4 weeks results in modest but significant blood pressure reduction. A whole-grain oat intervention study found a significant 5–6 mmHg reduction in systolic blood pressure over 12 weeks. The mechanism may involve gut microbiome-mediated improvements and reduced vascular inflammation.

The sodium content of sodium bicarbonate supplementation is a recognized concern for blood pressure in CKD patients. Clinical trial data are mixed: one meta-analysis reported a small risk of hypertension worsening, while a dedicated 8-week RCT found no significant effect on 24-hour ambulatory blood pressure. The sodium load (~6 mmol per 500 mg tablet) is an established pharmacological concern.

A 12-week RCT of B. animalis TA-1 combined with L. paracasei in subjects with metabolic syndrome risk factors demonstrated a significant reduction in systolic blood pressure versus placebo. An earlier study of B. animalis subsp. lactis BB-12 in subjects with metabolic syndrome did not find significant changes in blood pressure. Evidence is thus present but not consistent across strains and populations.

A double-blind, placebo-controlled crossover RCT (PRECISE study) found that 12-week supplementation with bilberry plus grape seed extract decreased ambulatory systolic and diastolic blood pressure by 4.7 and 2.3 mmHg respectively. A single-blind RCT also showed bilberry consumption reduced systolic blood pressure in subjects with cardiovascular risk factors.

A systematic review and meta-analysis of RCTs confirmed N. sativa significantly reduces systolic and diastolic blood pressure, with greater effect on SBP. N. sativa oil was more effective than seed powder. The 2025 meta-analysis of 82 RCTs confirmed significant improvements in SBP, DBP, and MAP.

Piperine has demonstrated antihypertensive properties in animal models and indirect support from human RCTs. A 12-week curcumin-piperine RCT in stroke rehabilitation patients found significant reductions in both systolic and diastolic blood pressure. Piperine is widely documented to have antihypertensive pharmacological activity.

Meta-analyses of multiple RCTs confirm that regular black tea consumption produces small but statistically significant reductions in both systolic and diastolic blood pressure. A 2021 dose-response meta-analysis of 13 RCTs found significant SBP and DBP reductions. Effect magnitudes are modest and most meaningful at population scale.

The WAHA randomized trial (n=305, 2 years) found walnut consumption produced a clinically meaningful reduction in systolic blood pressure (−4.61 mm Hg) versus controls. Black walnut contains ALA and arginine precursors associated with vasodilation. The Fitschen study specifically used black walnuts and examined cardiovascular markers.

Blackberry (Rubus ulmifolius) has been pharmacologically validated for vasodilatory and antihypertensive activity, with nutrigenomic studies identifying marker genes and bioactive molecules mediating hypotensive effects. Berry anthocyanins broadly show antihypertensive trends in clinical data, and blackberry leaf tea has traditional use for this purpose.

A. scholaris extracts have been shown to exert antihypertensive and vasorelaxant effects in spontaneously hypertensive rats and isolated aortic ring preparations. The mechanism involves calcium channel blockade, activation of soluble guanylate cyclase, and nitric-oxide-mediated endothelium-dependent relaxation.

Fucoidans exhibit ACE-inhibitory activity in vitro, and the 505-patient Gdue combination product clinical study showed blood pressure reductions. A small 30-person fucoidan human study found lower systolic blood pressure. Direct bladderwrack-specific antihypertensive RCTs are lacking.

Evidence from multiple RCTs and a major 2026 review of 12 clinical trials supports blood pressure reductions with blueberry intake, particularly in individuals with elevated cardiometabolic risk. However, results are inconsistent across trials, and some well-designed studies using 24-hour ambulatory monitoring showed no significant effect.

A clinical study in postmenopausal women with high blood pressure showed positive short-term effects of borage oil supplementation on blood pressure. GLA's role in prostaglandin E1 synthesis, which promotes vasodilation, provides the mechanistic basis. Evidence is limited to a small number of studies.

A 6-month clinical study in postmenopausal hypertensive women found borage oil supplementation (1,000 mg with vitamin E) produced significant reductions in both systolic and diastolic blood pressure. GLA's metabolite DGLA has documented vasodilatory and antiplatelet properties via PGE1.

CoQ10, the primary bioactive constituent in bovine heart, has been assessed for blood pressure effects in multiple RCTs and meta-analyses. A 2025 meta-analysis of 45 RCTs found CoQ10 significantly reduced systolic BP (WMD −3.44 mmHg). Taurine, also present in bovine heart, has additional blood pressure-lowering evidence. Evidence is constituent-based.

A meta-analysis of 10 clinical trials found that broccoli sprout supplementation significantly reduced systolic blood pressure by 10.9 mmHg and diastolic blood pressure by 6.95 mmHg. These effects are attributed to sulforaphane-mediated improvement in endothelial function, reduced oxidative stress, and decreased vascular inflammation.

Research from Temple University identified that compounds in brown rice's subaleurone layer inhibit angiotensin II, a key driver of hypertension. Animal models of hypertension (spontaneously hypertensive rats) showed pre-germinated brown rice significantly reduced both systolic and diastolic blood pressure. An 8-week RCT with brown rice bran in metabolic syndrome patients (n=50) found significant diastolic blood pressure reduction. Human evidence is currently limited and mostly derived from whole-grain dietary patterns.

Brussels sprouts supply potassium (~389 mg/100 g) that counters sodium-driven hypertension, and glucosinolates that support endothelial function. Cleveland Clinic identifies Brussels sprouts' glucosinolate and potassium content as specifically supporting healthy blood pressure.

Animal studies show that aqueous buchu extract normalizes elevated blood pressure in rats on a high-fat diet, with associated cardioprotective effects. This has not been confirmed in any human clinical trials. Traditional herbalists have also used buchu as a diuretic for hypertension management.

A clinical trial in knee osteoarthritis patients consuming burdock root tea (3 cups/day for 42 days) showed significant reductions in systolic and diastolic blood pressure (ScienceDirect, 2019). Animal studies with burdock seed ethanol extract demonstrated reduced impairment of acetylcholine-induced aortic relaxation in hypercholesterolemic rats, suggesting vascular benefits.

Butcher's broom acts as an alpha-adrenergic agonist, causing venous and arterial smooth muscle constriction via alpha-1 and alpha-2 receptor activation. This mechanism has been studied as a treatment for orthostatic hypotension (abnormally low blood pressure upon standing). A review and case report (Redman, J Altern Complement Med 2000) proposed R. aculeatus as a potential therapy for orthostatic hypotension, and some research supports this claim.

3-n-butylphthalide (3nB), the principal bioactive phthalide in celery, has demonstrated antihypertensive activity in both animal studies and the clinical celery seed extract trials. It acts as a calcium channel blocker and vasodilator, and is the primary mechanism behind celery's blood pressure-lowering effects.

Butyrate-producing bacteria are reduced in hypertensive patients, and there is a negative correlation between serum butyrate levels and blood pressure. Clinical trials combining butyrate with inulin show reductions in diastolic blood pressure in type 2 diabetic patients.

Cruciferous vegetables including cabbage were shown in a 2024 RCT to significantly lower 24-hour brachial systolic blood pressure in adults with mildly elevated BP. Anthocyanins from red cabbage are associated with lower central systolic blood pressure and reduced arterial stiffness in human cohort data. Potassium content in cabbage also contributes to blood pressure regulation.

A 2024 randomized controlled crossover trial (VESSEL study, PMC11367748) found that cruciferous vegetables (including cabbage) consumed at ~300 g/day for 2 weeks lowered 24-hour systolic blood pressure compared to a root/squash vegetable control in Australian adults with mildly elevated blood pressure. Epidemiological studies also link higher cruciferous vegetable intake to lower cardiovascular disease risk including blood pressure outcomes. Glucosinolates and potassium are the proposed mechanisms.

Hypotensive activity of C. crista has been noted in preclinical pharmacological reviews. The plant's cardioprotective studies in isoproterenol-induced models have measured blood pressure parameters. Hypotensive effects are listed as a documented pharmacological property.

Caffeine acutely raises systolic and diastolic blood pressure by increasing sympathetic tone and peripheral vascular resistance via adenosine receptor blockade. The effect is well-established in controlled trials, with doses equivalent to 2–3 cups of coffee (200–300 mg) producing measurable pressor responses. Habitual users develop partial tolerance, and individual response is modulated by CYP1A2 genotype.

EPA and DHA from marine sources including calamari oil have demonstrated modest but significant blood pressure-lowering effects in multiple meta-analyses. A J-shaped dose-response relationship suggests greatest reductions at 2–3 g/day of combined DHA+EPA. Effects are more pronounced in hypertensive and older populations.

Human studies have demonstrated that camu camu can reduce blood pressure. A 2017 crossover study in 20 healthy adults found that a single oral dose of camu camu pericarp extract improved flow-mediated vasodilation and lowered blood pressure versus placebo. A separate human trial also found blood pressure decreases alongside triglyceride reductions with lyophilized camu camu supplementation.

Rxlist/WebMD-level regulatory sources note that caprylic acid might lower blood pressure in some people, but this claim is based on very limited and indirect evidence. No dedicated human RCT establishes blood pressure lowering as a defined effect. The rating 'scientific' is marginal; the evidence is more mechanistic/observational than clinical.

Capsaicin activates TRPV1 in vascular endothelial cells, stimulating nitric oxide release and promoting vasodilation, with documented blood pressure-lowering effects in hypertensive animal models and some human studies. Population data associate spicy food consumption with reduced hypertension-related mortality.

Multiple meta-analyses of RCTs show capsaicin and capsinoid supplementation produces modest reductions in diastolic blood pressure, with fermented red pepper paste also reducing systolic blood pressure in longer trials. Results are consistent but effect sizes are small and dependent on dose and duration.

Multiple RCTs and meta-analyses demonstrate that green cardamom supplementation produces modest but statistically significant reductions in diastolic blood pressure, with more variable effects on systolic pressure. A 2024 meta-analysis of 8 RCTs (595 patients) found a significant diastolic reduction (WMD: −0.91 mmHg). Mechanistic pathways include antioxidant activity, nitric oxide modulation, and anti-inflammatory effects via NF-κB inhibition.

Daily carrot juice consumption reduced systolic blood pressure by approximately 5% in a human pilot study. Animal studies using carrot supplementation in hypertensive atherosclerosis-prone mice showed significant reductions in systolic, diastolic, and mean blood pressure. Potassium and nitric oxide–modulating compounds in carrots provide plausible mechanisms.

Hydrolyzed casein yields bioactive peptides that inhibit angiotensin-converting enzyme (ACE), reducing blood pressure. A 2025 double-blind randomized placebo-controlled trial in 114 prehypertensive/hypertensive adults found that hydrolyzed casein peptides (HCP-C7C12) significantly reduced systolic blood pressure by 9.41% and diastolic blood pressure by 9.53% over 8 weeks. A meta-analysis confirmed that casein-derived lactotripeptides reduce both systolic and diastolic blood pressure across randomized clinical trials.

Preclinical studies show cat's claw extracts have hypotensive activity, attributed to calcium-channel blocking effects of tetracyclic oxindole alkaloids. A 2021 mouse study (PMID: 34773881) showed that the hot-water extract AC-11 improved angiotensin II-induced hypertension. Traditional Uncaria species use for hypertension is also documented.

Catechins from green tea (especially EGCG) have documented antihypertensive effects in clinical trials and meta-analyses. A 2025 meta-analysis of 36 RCTs found catechin-rich green tea supplementation significantly reduced SBP and DBP, with effects strongest in hypertensive individuals. Mechanisms include ACE inhibition and eNOS upregulation.

Sulforaphane from cauliflower activates Nrf2-mediated antioxidant defenses in vascular endothelium, reducing oxidative stress that contributes to arterial stiffness and hypertension. Potassium content aids sodium balance. Animal studies show significant blood pressure prevention with SFN; some human trial data supports these effects.

A 2026 meta-analysis of 13 RCTs (n=821) found capsaicin supplementation significantly reduced diastolic blood pressure (−1.62 mmHg), though the finding was dependent on a single study and rated as low-certainty evidence. Mechanistically, capsaicin induces vasodilation via TRPV1 and CGRP release. Overall human RCT evidence is modest.

Celery and celery seed extract have clinical trial evidence for blood pressure reduction, primarily through bioactive 3-n-butylphthalide (3nB) and apigenin. A randomized triple-blind placebo-controlled trial found celery seed extract (1.34 g/day) reduced SBP from 141.2 to 130.0 mmHg and DBP from 92.2 to 84.2 mmHg in hypertensive patients.

Preclinical studies show that water-soluble alkaloids in A. aspera leaves lower blood pressure, increase respiration rate, and dilate blood vessels in animal models. Traditional use for hypertension is also widely documented.

Hesperidin from Chen Pi activates endothelial nitric oxide synthase, increasing NO-mediated vasodilation. Clinical trials and a 2023 meta-analysis of RCTs demonstrate modest but statistically significant reductions in systolic blood pressure and mean arterial pressure.

A 12-week RCT in older adults found that 480 mL/day of tart cherry juice significantly reduced systolic blood pressure versus placebo. Meta-analytic pooled data show mixed results, with low certainty evidence for SBP reduction and no significant effect in most pooled analyses. Effects may be stronger in older or hypertensive populations.

Multiple meta-analyses of RCTs confirm chia supplementation significantly reduces systolic blood pressure, with one analysis showing a significant −3.27 mmHg reduction in SBP in overweight subjects. Effects are most pronounced at doses ≥35 g/day and over ≥10 weeks. Diastolic BP reduction is less consistent across analyses.

Chickpea protein hydrolysates contain ACE-I inhibitory peptides that reduce blood pressure in preclinical models. An optimised alcalase-generated chickpea hydrolysate reduced systolic blood pressure by up to 47.35 mmHg in spontaneously hypertensive rats at 50 mg/kg. Human RCTs evaluating isolated chickpea peptides for hypertension have not yet been published.

Danshen demonstrates anti-hypertensive mechanisms including endothelial nitric oxide synthase enhancement, calcium channel inhibition, and vasodilation. Clinical data are mixed: one RCT showed no blood pressure reduction with Danshen water extract, while combination trials with Pueraria in high-risk hypertensives showed improved vascular function.

A 2017 meta-analysis of 19 RCTs found chlorella significantly reduced both systolic and diastolic blood pressure. A 2025 GRADE-reviewed meta-analysis similarly confirmed BP reduction. However, a 2025 Nutrients meta-analysis using different study selection found a neutral effect, indicating the evidence is real but not unequivocal.

Chloride has an independent role in blood pressure regulation beyond its co-transport with sodium. Clinical and dietary evidence suggests the chloride component of NaCl may be more important than sodium alone in driving salt-sensitive hypertension. The sodium-chloride cotransporter (NCC) in the renal distal tubule is a key mechanistic mediator.

A meta-analysis of controlled trials found that 6–8 weeks of chokeberry supplementation significantly reduces systolic blood pressure, with effects most pronounced in adults over 50. Individual RCTs in mildly hypertensive patients confirm modest but significant reductions. A 2025 MDPI systematic review found subgroup benefits particularly with preparations containing >50 mg/day anthocyanins.

Chrysanthemum has preclinical evidence for antihypertensive action via vasodilation and RAAS modulation, and is a traditional TCM herb for hypertension. Animal studies show blood pressure reductions of 5.7–9.6% with polyphenol-rich extract. Some clinical applications show auxiliary antihypertensive effects, but large RCT data in humans are limited.

Multiple meta-analyses of RCTs confirm that cinnamon supplementation produces modest but statistically significant reductions in both systolic and diastolic blood pressure. A 2020 meta-analysis of 9 RCTs (n=641) found SBP reduction of −5.17 mmHg and DBP of −3.36 mmHg. A 2024 umbrella meta-analysis also confirmed SBP and DBP reductions.

Multiple RCTs show hesperidin from C. sinensis produces modest but statistically significant reductions in systolic and diastolic blood pressure. Endothelial function improvement and reduced vascular inflammation are proposed mechanisms. A crossover RCT using C. sinensis juice also demonstrated blood pressure effects in healthy volunteers.

Multiple meta-analyses of RCTs consistently find CLA supplementation does not significantly alter systolic or diastolic blood pressure in humans. Despite animal data showing BP-lowering effects, this does not translate to meaningful antihypertensive effects in human trials.

Multiple meta-analyses of RCTs demonstrate that flavanol-rich cocoa products reduce both systolic and diastolic blood pressure. A Cochrane-reviewed meta-analysis of 10 RCTs found mean reductions of −4.5 mmHg systolic and −2.5 mmHg diastolic. A 2022 systematic review of 31 trials confirmed the effect is independent of baseline blood pressure status.

Cod liver oil produces modest blood pressure reductions, particularly in hypertensive individuals. Clinical and observational data support a small but consistent antihypertensive effect. The 2016 AHRQ evidence review, however, found high-strength evidence of no significant blood pressure effect in supplemented subjects overall.

Multiple clinical trials with CGA-rich coffee extracts have demonstrated significant reductions in systolic blood pressure. A Frontiers in Nutrition RCT (2023) found green coffee extract reduced systolic BP by −5.56 mmHg versus −0.90 mmHg in placebo (p=0.01). Chlorogenic acid improves vasoreactivity and endothelial nitric oxide signaling, which are the proposed mechanisms.

Pharmacological reviews of coix identify anti-hypertensive properties among its demonstrated activities. Coix inhibits COX enzymes and has anti-inflammatory effects that contribute to vascular health, and animal studies show blood pressure-related benefits.

Coleus forskohlii (containing forskolin) has been used traditionally in Ayurvedic medicine for heart conditions and hypertension, with pharmacological evidence showing blood vessel dilation and improved cardiac function via cAMP elevation. It is recognized as a blood pressure-relevant herb in multiple authoritative phytotherapy reviews.

Collard greens contain potassium (~220mg per cooked cup) which counteracts sodium-mediated blood pressure elevation. A study in spontaneously hypertensive rats showed collard green consumption led to a measurable decrease in systolic blood pressure. A broader observational study confirmed that green leafy vegetables including collards can decrease blood pressure and reduce cardiovascular disease risk.

Berberine from Coptis chinensis (Rhizoma Coptidis) demonstrates antihypertensive effects in spontaneously hypertensive rat models via gut microbiota modulation, SCFA production, LPS reduction, and STAT3 signaling. Clinical pharmacological studies list anti-hypertensive properties among berberine's cardiovascular actions.

Coenzyme Q10 has been evaluated in multiple meta-analyses of RCTs for blood pressure reduction. A meta-analysis of 12 RCTs found CoQ10 reduced SBP by up to 17 mmHg and DBP by up to 10 mmHg in hypertensive patients. Mechanisms involve antioxidant activity, endothelial function improvement, and enhanced nitric oxide bioavailability.

Cordyceps influences blood pressure through adenosine- and cordycepin-mediated stimulation of eNOS and NO production in endothelial cells, promoting vasodilation. A comprehensive review found evidence for Cordyceps' preventive or therapeutic effects on hypertension in preclinical and clinical data. ACE-inhibitory activity has also been proposed. Direct, high-quality human RCT evidence specifically targeting blood pressure reduction is not yet available.

Corn silk tea (CST) has been evaluated in multiple RCTs for antihypertensive efficacy. A 2019 systematic review and meta-analysis of five RCTs (n=567) found CST plus conventional antihypertensives significantly outperformed drugs alone. Methodological quality of included trials was generally poor, limiting conclusions. Proposed mechanisms include diuresis and flavonoid-mediated vasodilation.

A 2019 systematic review and meta-analysis of 5 RCTs (n=567) found that corn silk tea added to conventional antihypertensive drugs was significantly more effective than drugs alone in lowering blood pressure (RR=1.27; 95% CI: 1.17–1.38). The evidence quality is moderate due to methodological limitations in the individual trials.

Meta-analyses and RCTs show cranberry consumption produces modest reductions in systolic and/or diastolic blood pressure, particularly in individuals with elevated cardiovascular risk. A 2019 systematic review found cranberry administration significantly reduced systolic BP and BMI. Results across studies are heterogeneous, and effects in cardiovascular disease patients specifically may not reach significance in pooled analyses.

Cucumber contains ~147 mg potassium per 100 g with no sodium, which supports blood pressure reduction through natriuresis, vasodilation, and inhibition of renin release. A quasi-experimental clinical study in hypertensive patients examined cucumber juice and documented blood-pressure-related effects. The mechanism parallels that of dietary potassium supplementation.

A human crossover RCT found that an anthocyanin-rich blackcurrant beverage produced a significant effect on systolic blood pressure in exploratory analysis. Broader anthocyanin meta-analysis data are mixed, with some studies showing reductions and others not. Traditional and contemporary use for blood pressure support is documented.

Daidzin and daidzein demonstrate antihypertensive effects in animal models via vasodilation (nitric oxide upregulation, beta-adrenergic receptor blockade) and renin-angiotensin system modulation. Human data linking efficient daidzin metabolism to lower blood pressure exist from cross-sectional studies.

A published human pilot study (Clare et al., 2009; J Altern Complement Med; n=17) demonstrated a significant diuretic effect of dandelion leaf extract, which may indirectly support blood pressure reduction. Dandelion is also a notable dietary source of potassium, which supports vascular health. No human RCTs directly measuring blood pressure outcomes exist.

Danshen (Salvia miltiorrhiza) is a fundamental herb in Traditional Chinese Medicine for cardiovascular conditions including hypertension. Active tanshinones and salvianolic acids dilate coronary and peripheral vessels, inhibit ACE, and reduce sympathetic activation. Multiple clinical studies have confirmed antihypertensive effects.

Preclinical studies show Devil's Claw extract causes dose-dependent reduction of arterial blood pressure and heart rate in rats. A published case report in the Journal of Clinical Hypertension (2015) documented grade 2 hypertension in a normotensive woman during Devil's Claw self-administration. The cardiovascular effect is recognized by NCCIH and multiple clinical pharmacology databases.

DHA, the longest-chain marine omega-3 fatty acid, contributes significantly to the antihypertensive effects of fish oil. It improves endothelial function, reduces vascular resistance, and lowers blood pressure. Both standalone DHA and DHA+EPA meta-analyses confirm significant SBP and DBP reductions.

DHA supplementation consistently lowers systolic and diastolic blood pressure in RCTs, with DHA showing greater antihypertensive effect than EPA. The mechanism involves reduction of wall shear stress, IL-1β suppression, and improved vascular endothelial function. Clinical trials report moderate but statistically significant blood pressure reductions with algal DHA.

A randomised crossover trial in obese subjects found rosehip beverage (40 g/day powder) produced a statistically significant ~3.5% reduction in systolic blood pressure over 6 weeks compared with placebo. This finding was supported by the 2023 systematic review of RCTs, though results across dosages are mixed.

Dong Quai has documented vasodilatory effects mediated by ligustilide (calcium channel inhibition), coumarin derivatives, and antispasmodic actions on arterial smooth muscle. Pharmacological studies support blood pressure-lowering potential; TCM has used the herb for hypertension for centuries. Clinical trial evidence for antihypertensive effects of Dong Quai as monotherapy is limited.

DPA is classified alongside EPA and DHA as a long-chain n-3 PUFA with antihypertensive properties in epidemiological studies examining circulating LC n-3 PUFA and blood pressure. A meta-analysis of prospective cohort studies found circulating LC n-3 PUFAs (including DPA) inversely associated with risk of elevated blood pressure. DPA promotes vasodilation through anti-thrombotic eicosanoid shifts and endothelial nitric oxide support.

Dulse yields ACE-inhibitory peptides from its phycobiliproteins upon enzymatic hydrolysis, with peptide LRY showing an IC50 of 0.044 µmol in vitro. Dulse's potassium content also supports vasodilation. These mechanisms are scientifically documented at the in vitro level; human trials specifically for dulse and blood pressure have not been published.

EGCG is the primary active catechin in green tea, responsible for much of its antihypertensive effect. Clinical studies show it reduces both SBP and DBP through ACE inhibition, NO upregulation, and vascular oxidative stress reduction. Evidence derives from both isolated EGCG trials and green tea extract RCTs.

Eicosapentaenoic acid is a marine omega-3 fatty acid with well-documented blood pressure-lowering effects in multiple meta-analyses. It reduces vasoconstrictive eicosanoid production and improves endothelial function. Both NIH ODS and American Heart Association acknowledge its antihypertensive effects.

The clinical trial in 84 T2D patients treated with E. littorale pills for three months showed significant reductions in systolic and diastolic blood pressure as well as pulse rate. Animal studies also support antihypertensive-related effects, and a cardiac hypertrophy model showed cardiovascular normalization comparable to the reference drug losartan.

EPA, a key marine omega-3 fatty acid, is one of the primary components responsible for fish oil's blood pressure-lowering effects. It reduces production of vasoconstrictor eicosanoids, improves endothelial function, and lowers vascular resistance. Meta-analyses of EPA-containing omega-3 supplements confirm significant SBP and DBP reductions.

Multiple human and animal studies support eucommia's blood pressure-lowering effect. A controlled clinical trial in 24 prehypertensive adults found significant BP reduction with standardized bark extract at 500 mg three times daily for 8 weeks. A 2025 single-arm trial (n=17) showed mean SBP fell significantly, especially in CKD patients. Proposed mechanism involves nitric oxide upregulation and lignans acting on the renin-angiotensin system.

Eucommia ulmoides (du zhong) bark is a classical Chinese medicine herb specifically indicated for hypertension. Clinical trials in China have demonstrated significant blood pressure-lowering effects. Active compounds include chlorogenic acid, geniposidic acid, and lignans that inhibit the renin-angiotensin system and promote vasodilation.

Fava beans are rich in potassium, magnesium, and L-DOPA, all of which have established mechanisms for supporting healthy blood pressure. L-DOPA from fava beans is converted to dopamine, which stimulates nitric oxide production and vasodilation. Clinical trials of legume-rich diets show blood pressure reduction, particularly for systolic blood pressure.

Fennel demonstrates antihypertensive and vasorelaxant activity in preclinical studies, attributed to anethole, potassium channel modulation, and diuretic effects. It is listed as hypotensive in traditional Iranian medicine pharmacology. Human RCT data are not available.

A 2023 systematic review and meta-analysis of RCTs (Springer Nature, High Blood Pressure & Cardiovascular Prevention) was conducted to assess fenugreek's effect on systolic and diastolic blood pressure. A double-blind RCT in T2DM patients also showed significant reductions in diastolic blood pressure with 5 g/day fenugreek powder for two months.

Animal research has shown that F. asafoetida gum extract significantly reduces average arterial blood pressure. Multiple pharmacological reviews classify asafoetida as hypotensive. Traditional herbalism in Ayurveda and Unani also documents blood-pressure-lowering properties.

Ferulic acid reduces blood pressure by attenuating vascular oxidative stress, improving endothelial function, and increasing nitric oxide bioavailability. Multiple preclinical studies in spontaneously hypertensive and diet-induced obese rats demonstrate significant BP lowering. Human evidence is indirect but supported by its documented effects on vascular oxidative stress markers in RCTs; sodium ferulate has been used clinically in China for cardiovascular and cerebrovascular conditions.

Fisetin's senolytic clearance of senescent vascular endothelial cells reversed age-related endothelial dysfunction in old mice, a mechanism directly relevant to vascular tone and blood pressure regulation. Indirect anti-inflammatory and metabolic effects also support vascular health.

Fish oil is the primary dietary source of EPA and DHA omega-3 fatty acids, and among the most extensively studied nutraceuticals for blood pressure. Multiple large meta-analyses of RCTs confirm significant SBP and DBP reductions. Both AHA and NIH ODS formally recognize fish oil's antihypertensive effects.

Multiple RCTs show that riboflavin supplementation (1.6 mg/day) lowers systolic blood pressure by 6-13 mmHg specifically in cardiovascular disease patients homozygous for the MTHFR 677TT genotype, independently of antihypertensive drugs. This effect is mediated through FAD/FMN stabilization of MTHFR, with downstream effects on homocysteine and nitric oxide signaling.

Multiple meta-analyses of RCTs confirm flaxseed supplementation significantly lowers both systolic and diastolic blood pressure, particularly in individuals with hypertension or cardiovascular risk factors. A 2024 meta-analysis of 5 RCTs in hypertensive subjects found SBP reduced by −8.64 mmHg and DBP by −4.87 mmHg.

Multiple RCTs and meta-analyses have examined folic acid supplementation's effect on blood pressure, with consistently mixed but statistically significant results depending on dose and population. A large meta-analysis of 22 RCTs (n=41,633) showed folic acid supplementation significantly decreased systolic blood pressure (WMD: −1.10 mmHg; 95% CI: −1.93 to −0.28). Effects appear more pronounced in hypertensive patients with concurrent hyperhomocysteinemia and when doses of at least 5,000 µg/day are used. The primary mechanism proposed is improvement of endothelial function and reduction of plasma homocysteine.

Forskolin causes vasodilation by raising cAMP in vascular smooth muscle cells, lowering systemic vascular resistance. Small clinical studies from the 1980s–1990s demonstrated modest blood pressure reductions in humans, and the Godard 2005 RCT measured blood pressure as a secondary endpoint in overweight men.

A preclinical study in Journal of Ethnopharmacology (2004) showed Fritillaria water extract attenuated L-NAME-induced hypertension in rats via enhanced vascular NO generation and improved renal function. The Frontiers in Pharmacology review also notes fritillary's traditional use for hypertension and blood rheology regulation.

Ganoderma lucidum triterpenes inhibit angiotensin-converting enzyme (ACE) in vitro and have shown blood pressure-lowering effects in some earlier human trials, though a well-designed 16-week RCT and 2025 meta-analysis found no significant overall effect. Traditional use for hypertension is extensive.

Garbanzo beans contain potassium and magnesium—two minerals with established roles in blood pressure regulation—and their bioactive peptides produced by protease hydrolysis inhibit angiotensin-converting enzyme (ACE). Animal studies with chickpea protein hydrolysates show acute hypotensive effects of up to −47 mmHg. Epidemiologic pulse meta-analyses consistently list blood pressure as a benefited cardiometabolic risk factor.

Gardenia jasminoides extract has anti-hypertensive effects demonstrated in an L-NNA-induced hypertension mouse model, attributed primarily to geniposide. Treated mice showed significantly lower systolic, diastolic, and mean blood pressure than controls. Traditional use of Zhizi for hypertension is also well-documented.

Gardenia jasminoides demonstrated antihypertensive effects in an L-NNA-induced hypertension mouse model, with geniposide identified as the primary active component. GJ-treated mice showed significantly lower systolic, diastolic, and mean blood pressure vs. controls. A 2025 human study also showed gardenia floral volatiles reduced blood pressure and pulse in college students.

Multiple meta-analyses of randomized controlled trials confirm garlic supplements significantly reduce both systolic and diastolic blood pressure, particularly in hypertensive individuals. A 2020 meta-analysis of 12 trials found garlic lowered SBP by ~8.3 mmHg and DBP by ~5.5 mmHg. Mechanisms include allicin-mediated nitric oxide production, ACE inhibition, and vasodilation. Garlic also has extensive traditional use for cardiovascular conditions dating to ancient Egypt.

Multiple meta-analyses of randomized controlled trials confirm garlic bulb supplementation significantly reduces systolic and diastolic blood pressure. Mechanisms include allicin-mediated nitric oxide production, ACE inhibition, and vasodilation. Evidence is strongest in hypertensive individuals.

Gastrodin has clinical evidence for antihypertensive effects in Chinese populations, used as an adjunct to conventional antihypertensives. Animal studies show RAAS inhibition and PPARγ modulation as mechanisms. Clinical studies in China have documented blood pressure reduction.

A systematic review and meta-analysis of RCTs found genistein supplementation significantly reduced both systolic and diastolic blood pressure. A 2025 meta-analysis of diverse population RCTs found SBP reduced by a mean of 8.32 mmHg and DBP by 3.57 mmHg. Results across studies are somewhat inconsistent, with a 2019 meta-analysis of 6 RCTs also reporting significant reductions.

Ginger supplementation has been assessed in multiple RCTs and a systematic review and meta-analysis for blood pressure reduction, with significant effects found particularly in studies using higher doses and longer durations. Mechanisms include calcium channel antagonism, ACE inhibition, and vasodilatory prostaglandin effects.

Ginkgo biloba extract has been examined for cardiovascular effects including blood pressure modulation, largely through its vasodilatory and PAF-antagonist mechanisms. Some clinical evidence suggests modest effects on vascular tone. However, the evidence base for blood pressure specifically is not conclusive, and ginkgo is not recognized by major guidelines as a blood pressure intervention.

A systematic review and meta-analysis published in the Journal of Human Hypertension (17 RCTs, n=1,381) evaluated ginseng's effect on blood pressure, finding modest but clinically relevant improvements particularly in individuals with cardiovascular risk factors such as diabetes, metabolic syndrome, and obesity. Red ginseng contains hypotensive compounds (ginsenoside Rg3, arginine-fructose) that stimulate endothelial nitric oxide release, promoting vasodilation. Results across trials are somewhat heterogeneous.

GLA combined with EPA has lowered blood pressure in two clinical trials involving over 100 subjects. A 3-month GLA supplementation study in older subjects was associated with beneficial reduction in arterial hypertension. GLA is also theorized to reduce blood pressure via PGE1-mediated vasodilation, with supportive animal data showing dose-dependent BP reduction.

Evidence for glucomannan's effect on blood pressure is mixed. The Sood 2008 meta-analysis of 14 RCTs found no significant effect on blood pressure overall. However, the Vuksan et al. 1999 RCT in high-risk T2DM patients recorded a significant 6.9% reduction in systolic blood pressure with konjac-mannan fiber versus wheat bran placebo.

A published clinical trial (Díaz-Flores M et al., Can J Physiol Pharmacol, 2013) found oral glycine supplementation in metabolic syndrome patients reduced oxidative stress and improved systolic blood pressure. GlyNAC RCTs in older adults documented improvement in elevated systolic blood pressure. Glycine is also proposed to improve endothelial function through enhanced nitric oxide bioavailability.

Berberine from goldenseal has shown blood pressure-lowering effects in clinical research, with the Merck Manual stating berberine has been shown to lower blood pressure. Evidence comes from berberine trials, primarily in metabolic syndrome populations, with the same bioavailability caveat applying to whole goldenseal supplements.

A randomized, triple-blind, placebo-controlled add-on clinical trial (Ghaffari et al., Evidence-Based Complementary and Alternative Medicine, 2020) evaluated amla in uncontrolled hypertension. A systematic review of gooseberry for hypertension found prior studies suggested clinically meaningful blood pressure reductions.

Gotu Kola has demonstrated dose-dependent reductions in venous hypertension in multiple RCTs, and small studies suggest reductions in systolic and diastolic blood pressure in hypertensive patients. Its primary mechanism involves reduction of capillary permeability, connective tissue repair in vascular walls, and anti-inflammatory effects on the vascular endothelium.

Multiple meta-analyses of RCTs confirm grape seed extract significantly lowers blood pressure. A 2016 meta-analysis of 16 RCTs (810 subjects) found significant reductions in SBP (WMD −6.08 mmHg, P = 0.011) and DBP (WMD −2.80 mmHg, P = 0.001). A 2021 meta-analysis of 19 trials confirmed DBP reduction. Blood pressure-lowering effects are greatest in younger, obese, or metabolically disordered subjects.

Multiple RCTs and meta-analyses support GSE's ability to lower systolic blood pressure in pre- and mildly hypertensive subjects. A meta-analysis of 16 RCTs confirmed a significant positive effect. A 4-month RCT using 300 mg/day normalized blood pressure in 93% of supplemented pre-hypertensive subjects. Mechanisms include inhibition of endothelin-1 and enhanced nitric oxide-mediated vasodilation.

A meta-analysis of 3 RCTs found grapefruit consumption significantly reduced systolic blood pressure by approximately 2.4 mmHg in overweight adults. Individual trials have also noted significant systolic blood pressure reductions with daily grapefruit intake. Mechanistically, naringenin promotes nitric oxide production and vasorelaxation in vascular models.

A DBRPCT in healthy adults (N=28, 1500 mg/day, 4 weeks) found GMT significantly decreased systolic blood pressure by 10.8 mmHg and mean arterial pressure by 4.5 mmHg versus placebo. The Wightman et al. (2018) trial also measured blood pressure as a secondary outcome in 133 participants. Traditional use for blood pressure management is also documented.

Green chiretta demonstrates hypotensive and vasorelaxant effects primarily attributable to the diterpenoid 14-deoxy-11,12-didehydroandrographolide (AP3). Preclinical studies in conscious rats show dose-dependent blood pressure reduction, and one study in healthy subjects noted transient reductions at therapeutic URTI doses. Traditional use for hypertension is recorded in Malaysia.

Green tea supplementation has been confirmed in a 2025 meta-analysis of 36 RCTs to significantly reduce both systolic and diastolic blood pressure. Effects are stronger in individuals with elevated baseline BP. Active compounds include EGCG, catechins, and L-theanine.

A meta-analysis of six human studies found GS supplementation significantly decreased diastolic blood pressure. Animal studies consistently show dose-dependent antihypertensive effects. Human evidence is secondary to cardiovascular risk factor trials and requires larger dedicated trials for confirmation.

ACE-inhibitory peptides have been isolated from multiple Haliotis species, and animal studies show fermented abalone viscera significantly reduces systolic blood pressure in spontaneously hypertensive rats. Water extracts of abalone shell also reduced blood pressure in animal models.

Hawthorn (Crataegus spp.) has been used traditionally for cardiovascular conditions for centuries and is now supported by a 2025 meta-analysis of RCTs showing significant SBP reduction of ~6.65 mmHg in hypertensive patients. Active flavonoids and oligomeric procyanidins enhance nitric oxide production and vasodilation.

Multiple RCTs and meta-analyses show hesperidin (metabolized to hesperetin) reduces systolic blood pressure, though effects on diastolic pressure are less consistent. The antihypertensive effect is attributed to modulation of the renin-angiotensin system, improved endothelial function, and enhanced nitric oxide-mediated vasodilation. Individuals with elevated baseline blood pressure tend to respond most clearly.

Multiple RCTs and meta-analyses have examined hesperidin's effect on blood pressure with mixed but partially positive results. One 2023 dose-response meta-analysis found a significant reduction in systolic blood pressure (SBP), while diastolic BP was unaffected. A 2024 meta-analysis of nine RCTs (n=2,414) did not find statistically significant SBP changes, illustrating ongoing controversy. The CITRUS study (n=159) demonstrated that 12 weeks of hesperidin at 345–600 mg/day decreased SBP in people with elevated or stage-1 hypertension.

Hibiscus sabdariffa has multiple meta-analyses and RCTs demonstrating significant blood pressure reduction, particularly in stage 1 hypertension. Anthocyanins and other polyphenols inhibit ACE and upregulate nitric oxide synthase. Effects are comparable in some studies to low-dose antihypertensive medications.

Multiple rodent studies demonstrate antihypertensive effects of M. vulgare water extract in spontaneously hypertensive rats, with the diterpene marrubenol characterised as an L-type calcium channel blocker. Effects were comparable in some parameters to the calcium antagonist amlodipine. No human clinical trials for blood pressure have been conducted.

A double-blind RCT using Vaccinium arctostaphylos leaf extract demonstrated significant reductions in both systolic and diastolic blood pressure in hypertensive diabetic patients. Huckleberry's anthocyanins and flavonoids are documented to strengthen capillary walls and improve endothelial function through nitric oxide pathways. Larger meta-analyses show inconsistent results for blood pressure across Vaccinium anthocyanin trials.

Randomized controlled trials have shown that gum arabic supplementation reduces systolic blood pressure in type 2 diabetic and metabolic syndrome populations. A 12-week RCT showed significant decreases in both systolic and diastolic blood pressure. The 2023 systematic review confirmed altered blood pressure as a clinical outcome.

A human clinical trial (PMC4895752) in healthy volunteers found T. cordifolia at 150–300 mg/day for 28 days significantly reduced exercise-induced systolic and diastolic blood pressure versus placebo. The proposed mechanism is suppression of sympathetic nervous system overactivation. This is the primary human clinical evidence; additional large-scale trials are needed.

A 2021 meta-analysis of 7 RCTs found inositol supplementation significantly reduced systolic BP by 5.69 mmHg and diastolic BP by 7.12 mmHg. D-chiro-inositol specifically has been shown to lower blood pressure in PCOS populations. The effect is most pronounced in individuals with metabolic syndrome receiving approximately 4 g/day.

Inositol supplementation has been shown in a meta-analysis of RCTs to significantly reduce both systolic and diastolic blood pressure. IHN is also listed by WebMD as used for high blood pressure, though the quality of evidence specific to IHN is weak. The blood pressure effect is primarily attributed to the inositol component's role in insulin sensitization and the niacin component's vasodilatory action.

I. racemosa exhibits adrenergic beta-blocking activity in animal studies, a pharmacological profile associated with blood pressure reduction. At 400 mg/kg, petroleum ether root extract showed adrenaline-induced beta-blocking activity in rats. Traditional Ayurvedic and ethnomedicinal sources document hypotensive use.

A double-blind clinical trial showed jiaogulan achieved an 82% success rate in reducing high blood pressure, nearly matching indapamide (93%) and substantially outperforming Panax ginseng (46%). The mechanism involves stimulation of endothelial nitric oxide production leading to vasodilation.

Human RCT data on jujube and blood pressure are limited and inconsistent; one RCT noted no significant effect on blood pressure in overweight T2D patients consuming dried jujube. Potassium content may support vascular relaxation traditionally. Animal studies and preclinical evidence provide modest support for a hypotensive effect.

A prospective clinical study found that daily kale powder consumption for 8 weeks significantly reduced both systolic and diastolic blood pressure in adults with potential metabolic syndrome. Potassium and bioactive antioxidants such as quercetin in kale are the principal mechanisms proposed. Evidence links higher dietary potassium and quercetin intake with reduced blood pressure.

Multiple RCTs and a 2025 meta-analysis of 29 RCTs (1,583 participants) confirm edible algae including kelp species reduce blood pressure in humans. Mechanisms include alginate-mediated sodium binding, ACE-inhibitory peptides, and nitrate content. A crossover trial of seaweed fiber at 12–24 g/day in mild hypertensives showed significant mean blood pressure reduction.

Red kidney beans have been shown to acutely lower blood pressure in human crossover studies and to reduce pulse wave velocity. ACE inhibitory activity has been documented in germinated kidney bean extracts, suggesting a plausible mechanism beyond potassium and magnesium content.

A systematic review and meta-analysis of RCTs found that resveratrol supplementation significantly reduced systolic blood pressure, particularly at doses ≥300 mg/day and in trials lasting over 12 weeks. Effects were most pronounced in individuals with existing cardiometabolic conditions. The mechanism involves vasodilation via eNOS activation. Knotweed is traditionally used in China for hypertension.

Preliminary clinical evidence indicates that kudzu powder at 3 g/day for 12 weeks reduced systolic blood pressure by 16% and diastolic by 12% versus baseline in hypertensive patients. Animal studies with kudzu root extract show similar antihypertensive effects. Puerarin's vasodilatory mechanism via NO/eNOS upregulation and ET-1 reduction is well characterized.

L-arginine is the primary substrate for endothelial nitric oxide synthesis. Multiple meta-analyses of RCTs show L-arginine supplementation reduces both systolic and diastolic blood pressure, especially in hypertensive adults. A key mechanism is direct NO-mediated vasodilation.

L-Citrulline is converted to L-arginine in the kidneys, increasing NO production more efficiently than direct L-arginine supplementation. A 2019 meta-analysis of RCTs confirmed significant brachial SBP reduction of −4.49 mmHg and DBP of −3.63 mmHg. It is studied as a nutraceutical for hypertension.

NAC exerts vasodilatory properties that can improve blood flow and may help regulate blood pressure, partly through nitric oxide pathways and reduction of vascular oxidative stress. Clinical trials using NAC in diabetes and cardiovascular contexts have reported blood pressure-lowering effects. Evidence is modest and blood pressure is generally a secondary endpoint rather than primary in these trials.

Clinical trials in metabolic syndrome patients show that glycine supplementation at 5–15 g/day reduces systolic blood pressure. The GlyNAC 16-week RCT in older adults also documented improvement in blood pressure alongside other aging-related defects. Mechanistically, glycine improves endothelial function and reduces vascular inflammation.

Multiple human RCTs show that L-theanine attenuates stress-induced rises in blood pressure. A crossover trial in 14 adults found significant inhibition of mental-task-induced blood pressure increases in high-stress responders. A double-blind RCT in 48 adults showed that L-theanine (200 mg) blunted caffeine-induced blood pressure elevation without reducing alertness. Proposed mechanism involves reduction of sympathetic nervous system activation and preclinical evidence of eNOS-mediated nitric oxide production and arterial dilation.

Lactobacillus species, including L. acidophilus, have been studied within RCTs for blood pressure modulation. A meta-analysis of 18 RCTs found Lactobacillus supplementation significantly reduced systolic and diastolic BP, particularly in diabetic, Asian, and borderline hypertensive populations. L. acidophilus LA5 was specifically included in at least one RCT (156 overweight adults over 55) alongside B. lactis BB12 examining home blood pressure outcomes. The primary proposed mechanism is generation of ACE-inhibitory peptides during fermentation.

L. casei-containing probiotic formulas have been included in multi-strain intervention studies showing blood pressure regulation in at-risk populations, particularly in pre-diabetic and metabolic syndrome contexts. Mechanistically, gut microbiota modulation by L. casei may influence ACE inhibitor peptide production and systemic inflammation relevant to blood pressure regulation.

A subgroup meta-analysis of 7 RCTs focusing on L. plantarum found statistically significant blood pressure reductions in hypertensive participants but not in normotensive individuals. Effects are most pronounced in those with elevated baseline BP.

A randomized, double-blind, placebo-controlled pilot clinical trial demonstrated that fermented milk with L. lactis NRRL B-50571 reduced systolic and diastolic blood pressure in prehypertensive subjects, attributed to ACE-inhibitory peptides. In spontaneously hypertensive rats, the same fermented milk reduced SBP, DBP, heart rate, and had a hypolipidemic effect. The hypotensive effect was observed only in subjects with elevated baseline blood pressure.

Several RCTs have measured blood pressure as an outcome of lavender aromatherapy interventions, with multiple studies reporting significant reductions in systolic and/or diastolic blood pressure. A systematic review of 11 trials including 972 participants found physiological effects on blood pressure and other vital signs in three trials. A 2025 pilot RCT specifically targeted blood pressure in middle-aged hypertensive adults.

Clinical and observational evidence supports a modest antihypertensive effect of lemon. A Japanese cross-sectional study found daily lemon ingestion negatively correlated with systolic blood pressure. RCT data in AMI patients showed lemon aromatherapy reduced systolic BP, and a garlic-lemon juice RCT in hyperlipidemic patients demonstrated reductions in both systolic and diastolic BP.

A systematic review and meta-analysis of seven RCTs (n=305) found that M. officinalis intake was associated with a statistically significant reduction in systolic blood pressure (SMD: −0.56; 95% CI: −0.85, −0.27) with zero heterogeneity across studies. Proposed mechanisms include ACE inhibition by rosmarinic and related phenolic acids and GABA-mediated vasodilation.

Lemongrass tea has been shown to decrease blood pressure in both healthy and hypertensive human subjects in clinical studies. Citral promotes vasorelaxation via endothelial vasodilator secretion and calcium channel blockade in vascular smooth muscle. A comprehensive 2022 PMC review identified multiple human studies supporting this effect.

A meta-analysis of flaxseed supplementation trials found a mean reduction of 2.9 mmHg systolic and 2.4 mmHg diastolic blood pressure, with greater effects in trials lasting at least 12 weeks. Sesamin supplement trials have also indicated possible antihypertensive associations. Proposed mechanisms include antioxidant effects, modulation of renin-angiotensin-aldosterone signaling, and nitric oxide-mediated vasodilation.

A meta-analysis of 19 RCTs found fruit juice—including citrus—modestly but significantly reduced diastolic blood pressure. Lime's potassium, vitamin C, and flavonoid content are the proposed mechanisms. Evidence is stronger for the citrus class than for lime specifically.

Lotus seed alkaloids (neferine, liensinine, isoliensinine) exert antihypertensive effects in multiple animal models via eNOS/NO upregulation, ACE inhibition, calcium channel blocking, and renin-angiotensin system inhibition. Lotus seed bioactive peptides also show ACE-inhibitory activity. Human trials are absent.

Luteolin-containing nutraceutical combinations have shown blood pressure reduction in a human RCT in pre-obese subjects. Preclinical mechanisms include endothelial protection, anti-inflammatory effects on vascular smooth muscle, and antioxidant activity.

Multiple meta-analyses of RCTs indicate lycopene supplementation modestly but significantly reduces systolic blood pressure (SBP). A 2013 updated meta-analysis (6 trials) found a pooled SBP reduction of ~5 mmHg. Effect appears most pronounced at doses above 12 mg/day and in individuals with baseline SBP >120 mmHg. Diastolic blood pressure effects are not significant.

A small RCT in postmenopausal women found maca supplementation was associated with modest reductions in diastolic blood pressure. Animal studies also report blood pressure-lowering effects. Evidence is preliminary and insufficient to classify maca as an antihypertensive agent.

Tree nut meta-analyses including macadamia show modest blood pressure-lowering effects. A ScienceDirect review noted limited evidence suggesting nuts (including macadamia) have a protective effect on blood pressure and endothelial function. The MUFA and polyphenol content are the proposed mechanisms. Evidence specific to macadamia nuts for blood pressure is weaker than for cholesterol.

Magnesium supplementation has been shown in multiple RCTs and meta-analyses to modestly but significantly reduce blood pressure, particularly in magnesium-deficient or hypertensive individuals. A 2021 systematic review of 49 clinical trials confirmed antihypertensive effects. Mechanisms include vasodilation, calcium channel antagonism, and RAAS modulation.

Multiple animal studies show maitake SX-fraction significantly lowers systolic blood pressure in hypertensive and diabetic rodent models, via effects on the renin-angiotensin system and nitric oxide pathway. A human double-blind study in hypertensive patients reportedly found blood pressure reductions over 12 weeks. Traditional Asian use included hypertension management.

Multiple human clinical trials show mango intake produces modest reductions in blood pressure. A 2025 RCT in postmenopausal women found a 6.3 mmHg drop in supine systolic BP within 2 hours of mango consumption, and a 2.3 mmHg reduction in mean arterial pressure. A 6-week trial in lean adults showed a 4 mmHg systolic reduction.

Preclinical studies demonstrate antihypertensive effects of marjoram extract, with reduced aortic contractile responses to vasoconstrictors in rat models. Traditional use in Moroccan folk medicine specifically includes marjoram for hypertension.

Controlled-release melatonin has been cited by multiple authoritative reviews as having clinical evidence for blood pressure reduction. A 2025 dose-response meta-analysis confirmed melatonin supplementation significantly reduced systolic blood pressure (WMD: −2.34 mmHg). It modulates circadian blood pressure patterns and reduces sympathetic activity.

Meta-analysis evidence shows millet consumption reduces diastolic blood pressure by approximately 5% and systolic blood pressure by 4%, moving borderline-hypertensive values toward normal. This effect is attributed to millet's magnesium content and bioactive peptide fraction with ACE-inhibitory activity.

Momordica charantia has been evaluated for blood pressure effects in human RCTs as part of metabolic syndrome trials. A meta-analysis of nine RCTs found no statistically significant effect on systolic or diastolic blood pressure versus placebo. Preclinical evidence and traditional use for hypertension exist.

M. citrifolia noni juice significantly decreased systolic and diastolic blood pressure in spontaneously hypertensive rats in a 6-week study, operating via a GLP-1R-CaMKKβ-AMPK-eNOS endothelial pathway promoting vascular NO production. Traditional use of noni for hypertension is documented across multiple Pacific and Asian healing traditions.

Human RCT data indicate Morus preparations can reduce systolic and diastolic blood pressure. A 2024 crossover RCT in obese individuals showed significant reductions in systolic, diastolic, and mean arterial pressure with mulberry drink consumption. Proposed mechanisms include ACE inhibition and GABA content of leaves.

Aqueous extracts of A. vulgaris reversed noradrenaline-induced hypertension in isolated rat mesentery preparations, and moxibustion at acupoint KI 1 has shown blood-pressure-lowering effects in RCTs reviewed in a systematic review. Vasodilatory and hypotensive effects have been documented in animal models. Clinical data from moxibustion RCTs provide the most direct human-level evidence.

A clinical crossover RCT in obese adults found mulberry drink concentrate significantly reduced systolic and diastolic blood pressure and mean arterial pressure vs. placebo. Animal studies further support a blood pressure-normalising effect. TCM also uses mulberry leaf specifically for hypertension associated with 'Liver Yang rising'.

Mustard seed extracts have shown antihypertensive activity in animal models, reducing sodium levels and improving electrolyte balance. Isothiocyanates activate Nrf2 and may improve endothelial function; glucosinolate metabolites have been noted as hypotensive agents in phytochemical reviews. Clinical human data for mustard-specific blood pressure reduction are limited.

The 2024 systematic review on TC's cardioprotective effects reported evidence of blood pressure improvement. TC's antihypertensive properties have been documented preclinically and it is described in pharmacological reviews as an antihypertensive agent, though dedicated human BP RCTs are limited.

NAC has demonstrated blood pressure-lowering effects in clinical studies, primarily linked to its homocysteine-lowering and antioxidant properties. A reanalysis of two double-blind, placebo-controlled RCTs in 82 unmedicated middle-aged men found that 1.8 g/day NAC for 4 weeks significantly reduced systolic blood pressure in both normolipidemic and hyperlipidemic subjects.

Naringin lowers blood pressure in hypertensive animal models by modulating the renin-angiotensin system, normalizing ACE/ACE2 and AT1R/AT2R ratios. Population data show naringenin blood levels inversely correlate with systolic and diastolic blood pressure. Limited human trial evidence exists; one RCT with naringin supplementation showed improved cardiometabolic parameters including blood pressure.

Nattokinase, a serine protease from fermented soybeans (natto), has demonstrated significant antihypertensive effects in RCTs and a 2024 meta-analysis. A 2008 randomized controlled trial found 8-week supplementation reduced SBP and DBP in pre-hypertensive and stage 1 hypertensive adults. Mechanisms include fibrinolytic activity, renin inhibition, and improved blood viscosity.

Nattokinase significantly reduces both systolic and diastolic blood pressure in hypertensive individuals, confirmed by a 2023 meta-analysis of 6 RCTs (n=546) and a North American double-blind RCT. The proposed mechanism involves ACE inhibition and reduction of plasma angiotensin II levels.

Neem is recognised in traditional and pharmacological literature for antihypertensive effects, supported by mechanistic data on calcium channel blocking and endothelium-dependent muscarinic receptor activation. The metabolic syndrome RCT measured endothelial function (as a blood pressure surrogate). A ScienceDirect overview lists hypotensive properties among the documented activities of neem leaves.

Nettle has been studied as an antihypertensive in human and animal studies. A clinical trial in Lebanon prescribed nettle extract to mild hypertension patients over 16 weeks, with results suggesting reduction in both systolic and diastolic blood pressure via vasodilation, calcium channel blocking, and diuretic mechanisms. A review of multiple in vitro, animal, and clinical studies confirmed consistent blood-pressure-lowering findings.

Multiple human trials report that NR supplementation produces modest reductions in systolic and diastolic blood pressure, especially in individuals with above-normal baseline SBP. The largest pilot RCT observed an 8 mmHg reduction in systolic BP in the elevated-SBP subgroup after 6 weeks at 1,000 mg/day. A dedicated Phase IIa RCT (NCT03821623) is underway to confirm efficacy at 1,000 mg/day over 3 months.

The 2015 Onakpoya et al. meta-analysis of RCTs found significant reductions in systolic and diastolic blood pressure with Opuntia ficus-indica supplementation in overweight/obese individuals. Animal and review studies also document hypotensive activity, attributed to polyphenols and betalains. Human evidence, while present, is largely derived from secondary outcomes in cardiometabolic trials.

C. rotundus is listed as antihypertensive in pharmacological studies. The PMC 2018 review includes hypotensive and cardioprotective activities among proven properties. Animal studies confirm blood pressure-lowering effects attributed to vasodilatory and anti-platelet mechanisms.

Oat β-glucan consumption has shown blood pressure-lowering effects in several RCTs, particularly in hypertensive and obese subjects. Evidence is more consistent in populations with elevated baseline blood pressure; effects appear modest and results are mixed in normotensive individuals.

Okra has been investigated for blood pressure effects in RCTs, though results are inconsistent. The 2024 meta-analysis of nine RCTs found no significant overall effect on systolic or diastolic blood pressure, while GRADE assessment rated BP evidence as moderate quality with serious limitations in inconsistency and imprecision. Traditional use for blood pressure regulation is documented.

OA exhibits antihypertensive activity in animal models through diuretic/natriuretic mechanisms, direct heart rate reduction, and downregulation of sPLA2 and fatty acid synthase. In Dahl salt-sensitive hypertensive rats, OA prevented the development of severe hypertension over 6 weeks.

Dietary oleic acid consumption has been associated with blood pressure reduction in some human studies, though results are inconsistent. An epidemiological review noted that oleic acid consumption may reduce blood pressure and CVD risk, while RCTs show modest or non-significant effects. A direct comparison crossover study found borderline non-significant differences between oleic and linoleic acid-supplemented diets.

Oleuropein is the primary active polyphenol in olive leaves and fruit responsible for antihypertensive effects. It inhibits ACE, acts as a calcium channel antagonist, and reduces oxidative stress. Clinical evidence from RCTs of olive leaf extract standardized to oleuropein content shows significant SBP and DBP reductions.

Olive leaf extract (containing oleuropein) has been confirmed in multiple RCTs and a systematic review and meta-analysis to significantly reduce systolic and diastolic blood pressure in hypertensive and pre-hypertensive individuals. A 2022 meta-analysis found SBP reduction of −3.86 mmHg overall and −4.81 mmHg in hypertensive patients.

Both experimental and human clinical studies demonstrate anti-hypertensive effects of olive oil. EVOO's oleic acid and antioxidant polyphenols contribute to blood pressure reduction through improved endothelial function and nitric oxide bioavailability. A 2025 EFSA review supports olive oil phenolics in reducing systolic blood pressure.

Omega-3 fatty acids (EPA and DHA from fish oil) are among the most evidence-backed nutraceuticals for blood pressure reduction. The American Heart Association reports they can reduce SBP by 2–4 mmHg on average. NIH ODS formally acknowledges their BP-lowering effects, and multiple meta-analyses confirm the findings.

Mediterranean diets high in oleic acid (omega-9) from extra-virgin olive oil are associated with modest but significant reductions in diastolic blood pressure in large randomized controlled trials. OA's vasodilatory effect is linked to improved endothelial nitric oxide bioavailability and reduced vascular inflammation.

Human RCTs demonstrate that quercetin-rich onion skin extract reduces 24-hour ambulatory systolic blood pressure in hypertensive patients. A 2023 meta-analysis of 14 RCTs confirmed significant systolic blood pressure reduction with onion supplementation. The mechanism involves renal angiotensin receptor downregulation and increased urinary sodium excretion.

The Citrus study RCT demonstrated that hesperidin in orange juice reduces systolic blood pressure and pulse pressure in pre- and stage-1 hypertensive individuals. A 2024 meta-analysis found no significant pooled BP effect from hesperidin alone, but subgroup analyses and the Citrus study support benefit in hypertensive populations specifically.

Rice bran protein hydrolysates from Oryza sativa possess angiotensin-converting enzyme (ACE) inhibitory properties and have demonstrated blood pressure-lowering effects. Anthocyanins and gamma-oryzanol in pigmented rice varieties have also been reported to have antihypertensive properties.

Human clinical trials have shown that oyster mushroom consumption significantly reduces both systolic and diastolic blood pressure. The 2020 systematic review of 8 trials noted blood pressure reduction among reported benefits. HIV-positive individuals and diabetic subjects have both shown reductions in clinical studies.

In the Cardiovascular Health Study cohort, circulating palmitoleate showed associations with blood pressure markers. A longitudinal controlled trial of sea buckthorn seed oil (rich in POA) in hypertensive subjects found cardiovascular risk factor reductions including blood pressure effects.

Animal models and in vitro studies consistently demonstrate that parsley aqueous extract lowers both systolic and diastolic blood pressure via calcium channel blockade and vasodilation. The key active constituent is the flavone apigenin, abundant in parsley. Traditional use in Morocco specifically targets arterial hypertension. Robust human clinical trials remain lacking.

Human trials have shown stress-induced spikes in heart rate and systolic blood pressure are reduced following passionflower extract administration, primarily via anxiolytic mechanisms. Animal studies with Passiflora edulis peel extract (PFPE) demonstrate direct, significant reductions in systolic blood pressure in spontaneously hypertensive rats. A small human study in hypertensive patients using passion fruit extract showed reductions in BP readings, though methodological limitations apply.

Pea protein hydrolysates contain ACE- and renin-inhibitory peptides. In a 2011 human study, thermolysin-derived pea protein hydrolysate reduced blood pressure in hypertensive subjects. Pigeon pea hydrolysates showed −26 mmHg systolic reduction in hypertensive rats and antioxidant activity.

The evidence for peanuts and blood pressure is mixed but some trials suggest a modest benefit, particularly in hypertensive individuals. A 6-month peanut-enriched weight-loss RCT assessed blood pressure as a secondary endpoint. The ARISTOTLE RCT and a meta-analysis of peanut trials did not find consistent significant blood pressure reductions at the pooled level.

Pear polyphenols — including catechins, chlorogenic acid, and quercetin — have demonstrated blood pressure-modulating effects via nitric oxide-dependent vasodilation and endothelial protection. A PMC review of Mediterranean pear cultivars noted pears 'may improve the regulation of blood pressure and vascular function' in at-risk adults. Traditional Chinese medicine additionally attributes blood pressure-lowering properties to pear.

Pectin supplementation has been shown to improve blood pressure in animal studies, with proposed mechanisms involving microbiota-derived SCFAs, RAAS modulation, and natriuretic peptide regulation. Early human research suggests modest but measurable BP-lowering effects via high-fiber dietary patterns.

A 6-month randomized placebo-controlled trial in Japanese adults found Perilla frutescens leaf powder significantly reduced morning and nocturnal systolic blood pressure in prehypertensive subjects compared to placebo. The mechanism is attributed to ALA-mediated vascular effects and antioxidant activity reducing oxidized LDL.

Berberine from P. amurense has demonstrated antihypertensive effects in clinical and mechanistic studies, primarily through vasodilation via BKCa channel activation in vascular smooth muscle cells. An 8-week pilot RCT with a P. amurense plus citrus extract found beneficial effects on blood pressure in osteoarthritis patients. A 2025 meta-analysis found no significant effect on systolic or diastolic blood pressure at MetS-focused doses, indicating mixed evidence.

A 2024 meta-analysis of RCTs found phytosterol supplementation significantly lowered both systolic (−2.10 mmHg) and diastolic (−0.83 mmHg) blood pressure. A 2025 systematic review in metabolic syndrome patients reported systolic BP reductions of 3–5%. Effects are modest but consistent across multiple trials.

Multiple meta-analyses of RCTs show that pine bark extract (Pycnogenol) significantly reduces both systolic and diastolic blood pressure. Mechanisms include ACE inhibition and enhanced nitric oxide production causing vasodilation. Doses of 100–200 mg/day have been used in hypertension trials.

Pine bark extract (the base of Pycnogenol) contains oligomeric procyanidins and phenolic acids shown to reduce blood pressure in RCTs via ACE inhibition and nitric oxide-mediated vasodilation. Multiple meta-analyses of pine bark extract (primarily Pycnogenol) trials support modest antihypertensive effects.

Emerging clinical evidence suggests plant sterols can modestly lower blood pressure in individuals with metabolic syndrome when combined with a healthy dietary pattern. One 12-week crossover RCT in adults with metabolic syndrome found significant blood pressure reduction and improved endothelial function with 2 g/day of plant sterol-enriched soy milk. Evidence outside of a metabolic syndrome context is limited.

Clinical evidence supports modest blood pressure reduction from Plantago ovata (psyllium) supplementation, primarily through weight loss, improved insulin sensitivity, and gut microbiota-mediated mechanisms. The 2024 PMC review lists blood pressure lowering among five FDA-recognized benefits of P. ovata husk.

Psyllium (P. ovata) supplementation demonstrated significant blood pressure reduction in diabetic patients in a randomized clinical trial. A systematic review of Plantago RCTs found that among its documented health benefits, blood pressure lowering (secondary to weight loss) is one of five major FDA-recognized benefits. P. lanceolata has traditional use for hypertension.

Platycodon grandiflorum has been described as a traditional prescription to lower blood pressure in ethnopharmacological literature. Preclinical studies in spontaneously hypertensive rats demonstrate antihypertensive effects via angiotensin II/IGF-IIR pathway modulation. Animal evidence is more robust than human evidence.

Platycodon root is documented to possess hypotensive activity. A pharmacological review classifies it as 'an inhibitor of the central nervous system, which can reduce blood pressure.' A broader review lists hypotension among its established biological applications. The mechanism appears to involve central nervous system inhibition and vasodilation, though human RCT evidence is absent.

A 2019 systematic review and meta-analysis of 19 RCTs (24 arms) found policosanol significantly reduced both systolic blood pressure (WMD −3.42 mmHg) and diastolic blood pressure (WMD −1.47 mmHg). Individual RCTs in Korean and Japanese pre-hypertensive participants also show clinically meaningful reductions at 10–20 mg/day over 8–24 weeks. The mechanism is not fully established but may involve improvements in HDL functionality and cholesteryl ester transfer protein (CETP) inhibition.

A 2024 systematic review and meta-analysis of RCTs (38410857) confirmed pomegranate consumption lowers both systolic and diastolic blood pressure in adults. A 2025 cardiometabolic meta-analysis quantified SBP reduction (SMD: −0.49, p<0.001) and DBP reduction (SMD: −0.39, p<0.001). Doses of 50–200 ml/day juice have lowered SBP by 5–21% in some trials.

Pomelo's potassium content supports blood pressure regulation through sodium excretion, while naringenin plasma levels are inversely correlated with systolic and diastolic blood pressure in human observational data. Animal studies with naringin in high-fat/high-carbohydrate diet models demonstrate correction of diet-induced hypertension.

Potassium intake is inversely associated with blood pressure in numerous large clinical trials and meta-analyses. Increasing potassium reduces sodium retention, promotes vasodilation, and suppresses the renin-angiotensin system. The NIH ODS and WHO formally acknowledge its blood pressure-lowering effects.

A meta-analysis of RCTs found Opuntia ficus-indica consumption produced significant reductions in both systolic and diastolic blood pressure. Effects are modest in absolute magnitude but statistically significant. Traditional use for hypertension is also documented across multiple cultures.

Progesterone has a natriuretic effect via aldosterone antagonism that could theoretically lower blood pressure. A 3-month placebo-controlled RCT (n=133 postmenopausal women, OMP 300 mg/day) found no significant changes in systolic or diastolic blood pressure compared to placebo. Progesterone's blood pressure effects appear neutral at clinical doses in normotensive women.

A placebo-controlled clinical trial in 259 pre-hypertensive adults found 3–6 prunes daily for 8 weeks significantly reduced both systolic and diastolic blood pressure alongside lower LDL cholesterol. Prunes' high potassium content (280 mg per serving) is the primary proposed mechanism for vascular relaxation and sodium balance.

Prunus africana has documented traditional use for hypertension in East African communities, supported by its high phytosterol and polyphenol content. Prunus domestica contains potassium and chlorogenic acid with vasodilatory properties; a clinical study ('Use of prunes as a control of hypertension,' J Ayub Med Coll 2010) assessed prunes in hypertensive patients. The Prunus species metabolic syndrome review identifies blood pressure as one of the risk factors modulated by Prunus species.

A 2024 systematic review and dose-response meta-analysis (Food Science & Nutrition) of RCTs found that psyllium consumption significantly decreases systolic blood pressure (SBP), with the diastolic blood pressure (DBP) effect non-significant in pooled analyses. A 6-month open-label RCT in 141 hypertensive overweight patients found significant reductions in both SBP and DBP with psyllium. Effects are most consistent in patients with elevated baseline BP.

Pumpkin seed oil has demonstrated antihypertensive activity in both animal models and human clinical studies. In postmenopausal women, 3 g/day PSO significantly reduced brachial and central systolic blood pressure. Pumpkin flesh provides potassium, and its flesh/seed combination reduced mean arterial pressure in a genetic hypertension rat model independent of ACE inhibition.

Punarnava has been investigated as an antihypertensive agent both in animal studies and in one small Ayurvedic clinical study (AYUSHDHARA, 2015) in essential hypertension patients. Its blood pressure-lowering effect is linked to its diuretic activity and vasodilatory properties via liriodendrin (a calcium channel antagonist). Traditional use as a diuretic for hypertension is well-documented.

Systematic reviews of RCTs show purslane reduces both systolic and diastolic blood pressure, with the most robust effects in diabetic patients at 12 weeks of supplementation. A 2025 GRADE-assessed meta-analysis confirmed diastolic blood pressure reductions (WMD: −1.60 mmHg) in 12-week trials. Purslane's potassium content and natural diuretic properties are implicated.

Pycnogenol, a standardized extract from French maritime pine bark rich in procyanidins, has been assessed in multiple RCTs and several meta-analyses for blood pressure effects. A 2018 meta-analysis of 9 trials found beneficial effects on BP. Mechanisms include ACE inhibition and NO-mediated vasodilation.

Quercetin, a ubiquitous dietary flavonoid, has been assessed in multiple RCTs and meta-analyses for blood pressure reduction, with significant effects in hypertensive individuals at doses of 500–1,000 mg/day. Mechanisms include inhibition of ACE, reduction of oxidative stress, and improvement of endothelial function.

A 1-year parallel RCT in 138 impaired glucose tolerance subjects found significant reductions in both systolic and diastolic blood pressure in the quinoa group versus controls. A quinoa cereal bar trial also noted modest blood pressure reductions. Quinoa's magnesium, potassium, dietary fiber, and polyphenols are mechanistically linked to vasodilation and blood pressure regulation.

Radish leaf ethyl acetate extract significantly reduced systolic blood pressure in spontaneously hypertensive rats by increasing serum nitric oxide and antioxidant enzyme activity. Radish is also a documented source of dietary nitrates and potassium, which support vasodilation. All mechanistic and interventional evidence is from animal studies.

Evidence for red clover's effect on blood pressure is mixed. Most RCTs in normotensive populations show no significant change. However, a small crossover RCT in postmenopausal women with type 2 diabetes found significantly lower daytime systolic and diastolic ambulatory blood pressure during isoflavone therapy. Effects may be context-dependent (hypertension or metabolic comorbidity).

Evidence for RYR's effect on blood pressure is mixed but leans toward modest systolic benefit, particularly when combined with conventional antihypertensive therapy or olive extract. A meta-analysis of 21 RCTs (4,558 patients) found that RYR plus conventional therapy significantly lowered systolic blood pressure versus placebo plus conventional therapy. However, RYR as monotherapy shows inconsistent effects on diastolic pressure, and several individual RCTs show no significant BP change. The NIH NCCIH lists blood pressure reduction among potential effects of high-monacolin-K products.

Antihypertensive effects of Rehmanniae Radix are supported by preclinical studies. A Korean literature review confirmed antihypertensive effects were among properties measured in Rehmannia extracts. A broader PMC review noted Rehmanniae Radix is effective in treating metabolic diseases including high blood pressure.

Reishi has been used traditionally in TCM for hypertension. Preclinical studies and small human trials suggest antihypertensive effects, and early human research showed reishi reduced chest pain and shortness of breath in coronary artery disease. However, the Cochrane systematic review (2015) found no statistically significant blood pressure reduction in pooled RCTs. Evidence is present but inconclusive at the human clinical level.

Resveratrol, a polyphenolic stilbene from grapes and red wine, has been tested in multiple RCTs for blood pressure reduction. A systematic review and meta-analysis found significant diastolic blood pressure reduction, with evidence for both SBP and DBP effects in specific dosing ranges. It modulates NO bioavailability and vascular oxidative stress.

Rhubarb root is traditionally listed in TCM for hypertension, and a human RCT in type 2 diabetics showed significant reductions in systolic and diastolic blood pressure after one month of rhubarb extract supplementation. A lipid-lowering review also notes its blood pressure-reducing properties.

Chlorogenic acids from green coffee have demonstrated blood pressure-lowering effects in human crossover trials. A pilot crossover study found that green coffee consumption significantly reduced systolic and diastolic blood pressure compared to baseline by influencing 11β-HSD1 enzyme activity. Epidemiological evidence on habitual coffee and blood pressure is complex; short-term caffeine intake causes transient rises, but long-term consumption shows neutral or inverse associations with hypertension.

Multiple RCTs and a systematic review have documented blood pressure-lowering effects of rosehip supplementation, particularly in overweight adults. A 6-week RCT (n=31, 40 g rosehip powder daily) demonstrated significant reductions in systolic blood pressure. Proposed mechanisms include ACE inhibition and vascular antioxidant protection.

Clinical evidence from a double-blind crossover RCT demonstrated a statistically significant reduction in systolic blood pressure of approximately 3.4% with 40 g/day rose hip powder for 6 weeks in obese individuals. A mild blood pressure-lowering effect has been confirmed across multiple analyses. The effect may be mediated by antioxidant flavonoids and a mild diuretic action.

A pilot clinical trial described as the first human investigation of rosemary infusion's antihypertensive effects found preliminary evidence of blood pressure reduction. Traditional use for both low and high blood pressure is long-established. Human clinical data specifically for rosemary monotherapy in hypertension remains limited.

Rosmarinic acid has demonstrated antihypertensive effects in multiple preclinical models via ACE inhibitory and vasodilatory mechanisms. In angiotensin-II-treated hypertensive rats, both acute and chronic RA lowered blood pressure dose-dependently. In fructose-fed rats, RA (10 mg/kg for 45 days) improved blood pressure alongside metabolic markers.

A double-blind, placebo-controlled RCT (n=86) found RJ (1,200 mg/day, 4 weeks) significantly improved diastolic blood pressure versus placebo (p=0.032). Preclinical data indicate ACE-inhibitory peptides in RJ underlie this effect. Evidence is limited to one small human trial.

R. cordifolia demonstrates vasodilatory and calcium channel blocking activity in preclinical models, relaxing smooth muscle of the heart and blood vessels analogously to standard calcium channel blocker drugs. Vasodilating properties are listed among its confirmed pharmacological activities in cardiac health research. Traditional Ayurveda also recognizes its use as a vasodilator.

A double-blind, randomized, placebo-controlled trial in 50 type 2 diabetes patients found that 1 g/day rutin for three months significantly improved systolic blood pressure, diastolic blood pressure, mean arterial pressure, pulse pressure, and heart rate. Rutin is recognized pharmacologically for increasing blood flow and maintaining capillary elasticity.

Whole-grain rye has been associated with lower blood pressure in the context of diets rich in whole grains, with viscous soluble dietary fiber shown to lower both systolic and diastolic blood pressure. The Frontiers in Nutrition 2025 review confirmed that whole-grain rye is associated with improved lipid profiles, lower blood pressure, and reduced inflammation. Dedicated rye-specific blood pressure RCTs are sparse.

A randomized, double-blind, placebo-controlled trial in 67 metabolic syndrome patients found that 8 g/day safflower oil for 12 weeks significantly reduced systolic blood pressure compared to placebo. Animal studies also show that C. tinctorius extract inhibits hemodynamic alteration and vascular remodeling in hypertensive rat models through antioxidant mechanisms.

Meta-analyses of RCTs confirm small but statistically significant reductions in both systolic and diastolic blood pressure with saffron supplementation. A 2022 meta-analysis of 32 RCTs (n=1,674) found a significant SBP reduction of −3.42 mmHg. An earlier meta-analysis reported a significant diastolic BP reduction of −1.24 mmHg. Effects are modest and do not substitute for antihypertensive medication.

Salvianolic acids (A and B) from danshen (Salvia miltiorrhiza) have documented ACE-inhibitory and endothelium-protective antihypertensive properties. They protect NO from oxidative degradation, inhibit ACE, and reduce vascular inflammation. Both in vitro and animal evidence supports these effects, with clinical evidence from danshen preparations.

A preclinical study on Smilax aristolochiifolia in obese mice reduced systolic blood pressure by ~31% and diastolic by ~37%. Traditional use for hypertension is globally documented since the 1500s. Evidence is from a single animal study; no human blood pressure trials have been conducted.

Animal and cell studies show schisandra lignans have the potential to lower blood pressure via vasorelaxation mechanisms. An in vitro study demonstrated schisandra extract causes endothelium-dependent and independent relaxation of isolated rat thoracic aorta. The broader ScienceDirect pharmacology overview includes blood pressure regulation among schisandra's documented effects.

Hypotensive activity is one of the most consistently reported pharmacological effects of S. ningpoensis root. Animal studies with ethanolic root extract demonstrated significant reductions in systolic, diastolic, and mean arterial blood pressure. The compound angoroside C specifically reduces blood pressure in experimental models. Traditional Chinese medicine also describes the root as lowering blood pressure.

SDG and its mammalian lignan metabolites are reported to lower blood pressure through antioxidant preservation of nitric oxide bioavailability and reduction of vascular oxidative stress. The British Journal of Nutrition review identified blood pressure reduction as one of the cardioprotective mechanisms of SDG metabolites. Human FLC studies in type 2 diabetics (600 mg SDG/day) showed directional decreases in blood pressure parameters.

Multiple controlled trials and meta-analyses confirm sesame consumption significantly reduces both systolic and diastolic blood pressure. A 2017 meta-analysis of eight controlled trials (843 participants) found SBP reductions of ~7.8 mmHg and DBP reductions of ~5.8 mmHg. Active constituents include lignans (sesamin), polyunsaturated fatty acids, phytosterols, and fiber. Evidence quality is moderate with high heterogeneity across studies.

Shiitake contains phytonutrients and potassium that are associated with blood pressure regulation. Animal studies (including spontaneously hypertensive rats) have shown blood pressure reduction with shiitake feeding. Adenosine in shiitake may inhibit platelet aggregation and promote vasodilation. Human-specific blood pressure evidence is limited to indirect data.

A meta-analysis of cross-sectional studies in Chinese populations found a significant inverse association between spicy food intake (including Sichuan-style foods with Z. bungeanum) and hypertension. Preclinical studies identify anti-inflammatory and lipid-modulating mechanisms consistent with vascular benefit. Direct human RCT evidence for Z. bungeanum alone is absent.

Animal studies show P. hydropiper leaf extracts reduce blood pressure and heart rate in salt-induced hypertensive mice in a dose-dependent manner. Traditional use for hypertension is also documented. No human trials have been conducted.

The relationship between dietary sodium intake and blood pressure is one of the most extensively documented in cardiovascular medicine. Multiple RCTs and meta-analyses confirm that reducing sodium intake lowers blood pressure in both hypertensive and normotensive individuals. A dose-response relationship is well-established, though individual salt-sensitivity varies considerably.

Quercetin and rutin from S. japonica have been shown to inhibit ACE and induce vasodilation in pharmacological models. S. japonica is listed in classical TCM for hypertension treatment. Some clinical literature on rutin evaluates blood pressure parameters, though results vary by dose and population.

A. muricata leaf extracts reduce blood pressure in rodent hypertension models via antioxidant, anti-inflammatory, and vasodilatory mechanisms. In vitro ACE-inhibitory and hypotensive properties have been documented. Antihypertensive use is also a longstanding traditional application.

Meta-analyses of RCTs show soy isoflavones produce significant blood pressure reductions, particularly in hypertensive individuals. A 2024 meta-analysis of 24 RCTs found significant SBP and DBP reductions. Normotensive subjects show minimal effect.

A 2024 meta-analysis of 24 RCTs (1,945 participants) found soy isoflavone supplementation significantly reduces both systolic and diastolic blood pressure, with more pronounced effects in metabolic syndrome or prehypertensive individuals and interventions ≥6 months.

A meta-analysis of 11 randomized controlled trials found soy isoflavones significantly reduced systolic and diastolic blood pressure in hypertensive subjects, but not in normotensive individuals. Several meta-analyses of epidemiological and clinical trials have shown dietary soy isoflavones lower blood pressure sufficiently in hypertensive and pre-hypertensive subjects to reduce overall cardiovascular risk. Isoflavones appear to act through enhancement of endothelial nitric oxide synthase activity, improving vasodilation.

Spearmint contains carvone, which acts as a calcium-channel-like antispasmodic on vascular smooth muscle, and a 2024 systematic review/meta-analysis of Mentha RCTs found Mentha consumption was associated with blood pressure improvement. Direct large-scale spearmint-specific human RCT data on blood pressure remain limited.

Hypotensive activity is listed among scientifically evidenced activities of S. indicus in the PMC phytopharmacological review. The Meratrim blend meta-analysis also found significant blood pressure reductions in obese humans. Preclinical mechanistic data suggest effects via nitric oxide pathways and anti-inflammatory vascular protection.

Multiple RCTs demonstrate that dietary nitrate from spinach significantly lowers both central and peripheral systolic and diastolic blood pressure through the nitrate–nitrite–nitric oxide pathway. Effect sizes of ~3–5 mmHg systolic reduction are consistently reported across 7-day intervention periods.

A meta-analysis of 5 RCTs (n=230) found spirulina supplementation significantly lowered systolic BP (MD: −4.59 mmHg) and diastolic BP (MD: −7.02 mmHg), particularly in hypertensive patients. Additional trial data shows 8 g spirulina acutely decreased systolic BP by 4% in healthy young adults. Proposed mechanisms include ACE-inhibitory tripeptides, nitric oxide pathway modulation, and phycocyanin-mediated reduction of oxidative stress in the vasculature.

Multiple human RCTs have evaluated stevia's antihypertensive effects. A landmark multicenter, double-blind, placebo-controlled study of 106 hypertensive subjects found stevioside (250 mg three times daily) significantly reduced systolic BP from ~166 to ~153 mmHg and diastolic from ~102 to ~90 mmHg after 3 months, sustained over 1 year. A meta-analysis of steviol glycoside RCTs found an overall significant systolic BP reduction (MD: −6.32 mmHg). Results are mixed in normotensive individuals.

Human RCTs and meta-analyses show SGs reduce systolic blood pressure, with the most robust effect seen in patients with mild hypertension using higher stevioside doses. A 2019 meta-analysis of nine RCTs (n=462) found a significant systolic BP reduction of −6.32 mmHg vs. placebo. Effects at typical sweetener doses and with rebaudioside A are less consistent.

RCT evidence shows strawberry consumption can reduce systolic blood pressure and arterial stiffness in pre- and stage 1-hypertensive postmenopausal women. A 2023 RCT in healthy older adults found 26 g/day of freeze-dried strawberry powder lowered systolic blood pressure. However, a 2025 meta-analysis of 8 RCTs found no significant overall effect on BP, with mixed subgroup findings.

Sulforaphane's clinical trials for hypertension have not demonstrated significant blood pressure reductions. Mechanistic evidence supports endothelial protection and vascular anti-inflammatory effects, but the comprehensive clinical trial review explicitly noted no benefits for hypertension from SFN metabolic trials.

Clinical evidence shows sunflower seeds and oil can modestly reduce systolic blood pressure. A 3-week trial in women with type 2 diabetes consuming 30 g/day sunflower seeds noted a 5% reduction in systolic blood pressure. Unrefined sunflower oil enriched with phospholipids showed a more pronounced lowering of diastolic blood pressure in hypertensive, obese subjects.

Limited clinical evidence suggests sunflower oil may modestly contribute to blood pressure reduction, particularly diastolic BP, when consumed as part of a dietary intervention. A study using phospholipid-enriched sunflower oil showed greater diastolic BP lowering vs. refined sunflower oil alone. Evidence is modest and effects are not consistently significant across all trials.

A. calamus extract demonstrates antihypertensive and coronary vasodilatory effects in preclinical models. A 2012 PubMed study in bovine coronary arterial preparations showed the extract causes cardiac depressant and EDHF-mediated coronary vasodilation via potassium channel activation. Traditional use for vascular disorders is documented.

Szechuan lovage and its bioactive compound TMP have demonstrated antihypertensive effects through vasodilation and calcium channel modulation. Hypertension is explicitly listed among the cardiovascular conditions for which CX shows significant pharmacological effects in peer-reviewed reviews. Ferulic acid from CX has also been clinically used for hypertensive diseases in China.

Tanshinones are the primary active diterpenoids from danshen (Salvia miltiorrhiza) with documented vasodilatory and antihypertensive effects. They inhibit ACE, relax vascular smooth muscle, and reduce angiotensin II-induced vasoconstriction. Evidence comes from pharmacological and some clinical studies of danshen preparations.

Taurine, a sulfur-containing amino acid, has clinical trial evidence for blood pressure reduction, including from a 2024 meta-analysis of RCTs. It inhibits the renin-angiotensin system, reduces sympathetic tone, and acts as an osmoregulator in vascular tissue. Effects on SBP and DBP have been confirmed in controlled studies.

T. arjuna bark demonstrates clinically documented hypotensive activity. A randomized, double-blind, placebo-controlled trial in hypertensive geriatric patients found 1,000 mg/day for 12 weeks significantly reduced both systolic and diastolic blood pressure alongside improved antioxidant status. Pre-clinical studies confirm coronary vasodilatory and inotropic mechanisms.

Aqueous extracts of Thymus serpyllum (wild thyme) normalized arterial blood pressure in spontaneously hypertensive rats (SHR) in multiple animal studies, attributed to rosmarinic acid's vasodilatory and HO-1-mediated mechanisms. A Frontiers in Nutrition (UCL) review noted these cardiovascular effects have been observed predominantly in rodent models, and controlled clinical trials in humans remain lacking.

A 12-week RCT in metabolic syndrome patients showed tocotrienol-enriched supplementation reduced systolic blood pressure by 4.2% and diastolic by 5.3%. Human studies also confirm tocotrienols support endothelial health relevant to blood pressure regulation. Animal data show blood pressure normalization, though large dedicated human BP trials are lacking.

Lycopene supplementation has consistently demonstrated significant reductions in systolic blood pressure across multiple meta-analyses of randomized controlled trials. A 2017 meta-analysis of 21 trials found lycopene reduced systolic BP by 5.66 mmHg. A 2026 umbrella review confirmed high-certainty evidence for blood pressure improvement at doses of 5–30 mg/day lycopene.

The only human RCT of pterostilbene monotherapy (n=80, 6–8 weeks) showed significant reductions in both systolic (−7.8 mmHg, p<0.01) and diastolic blood pressure (−7.3 mmHg, p<0.001) at 125 mg twice daily. Mechanisms include ACE inhibition and nitric oxide synthase upregulation.

Clinical evidence from RCTs, including a 2025 Scientific Reports trial, demonstrates curcumin significantly reduces systolic and diastolic blood pressure, particularly in metabolically compromised individuals. Meta-analyses confirm directional antihypertensive effects, though results are somewhat conflicting across studies. Mechanisms involve endothelial protection and anti-inflammatory effects.

A 2025 meta-analysis of 45 RCTs found CoQ10 significantly reduced systolic blood pressure (WMD −3.48 mmHg). An earlier 2007 meta-analysis of 12 trials reported reductions up to 17 mmHg systolic and 10 mmHg diastolic in hypertensive patients. Ubiquinol's mechanism involves enhancing SOD activity, preserving nitric oxide bioavailability, and improving endothelial function.

In animal models, vanadyl sulfate and BMOV have consistently lowered blood pressure in spontaneously hypertensive and hyperinsulinemic rats. The proposed mechanism links blood pressure reduction to improved insulin sensitivity. The single human study examining blood pressure found no significant change at supplemental doses, though the evidence base is very limited.

Three RCTs have demonstrated that low-dose riboflavin supplementation (1.6 mg/day for 16 weeks) significantly lowered blood pressure in hypertensive patients carrying the MTHFR 677TT genotype. This effect is genotype-specific and operates by stabilizing the FAD-dependent MTHFR enzyme and lowering homocysteine. A Cochrane-registered review (2025) notes the overall evidence remains very uncertain.

Nicotinic acid (niacin) has been shown to lower systolic and diastolic blood pressure in hyperlipidemic patients, with evidence from post-hoc analyses of large trials including the Coronary Drug Project. The mechanism may involve prostaglandin-mediated vasodilation independent of lipid effects. Both immediate- and extended-release forms have shown dose-dependent BP-lowering effects.

Epidemiological data from large US cohorts associate higher vitamin B6 intake with significantly lower prevalence of hypertension. Mechanistic evidence suggests PLP modulates vascular calcium transport via P2X purinergic receptors and reduces sympathetic activity, supported by animal and early human supplementation data.

Folate deficiency is associated with increased hypertension risk, with a large prospective cohort (n>219,000) finding a 42% higher risk of hypertension in folate-deficient individuals. Folate's blood pressure effects are mediated partly through homocysteine lowering and through MTHFR-dependent nitric oxide production. Folic acid supplementation has shown blood pressure-lowering effects in patients with H-type hypertension (hypertension combined with hyperhomocysteinemia).

Vitamin C (ascorbic acid) supplementation has been shown in meta-analyses of RCTs to modestly reduce systolic blood pressure. It enhances nitric oxide bioavailability by protecting it from oxidative degradation. The NIH nutraceutical literature cites vitamin C among supplements with BP-lowering evidence.

Wasabi supplementation reduced systolic blood pressure in diet-induced hypertensive rats. Wasabi leaf extract has also been shown to reduce blood pressure in animal studies. The antihypertensive mechanism may involve Nrf2/HO-1 pathway activation and anti-inflammatory effects on vascular endothelium. No human clinical trials have specifically evaluated wasabi's effect on blood pressure.

Watermelon is the principal dietary source of L-citrulline, which converts to L-arginine and raises nitric oxide bioavailability, promoting vasodilation. Multiple RCTs and meta-analyses confirm significant reductions in both systolic and diastolic blood pressure. Effects are most consistent with watermelon extract/concentrate delivering ≥6 g L-citrulline/L-arginine daily.

Whole-grain wheat intake is the most consistently demonstrated cardiovascular benefit from wheat in RCTs. A 12-week RCT showed 3 daily servings of whole-grain foods (wheat/oats) significantly reduced systolic blood pressure in middle-aged adults. An RCT in overweight adults found diastolic blood pressure improvement was >3-fold greater with whole-grain vs. refined grain diets.

Multiple RCTs and a dose-response meta-analysis of 18 RCTs (n=1,177) confirm that whey protein supplementation significantly reduces systolic blood pressure (SBP) by approximately 1.5 mmHg on average. The Whey2Go RCT (n=42, double-blind crossover) found significant 24-hour ambulatory SBP and DBP reductions with 56 g/day for 8 weeks. Bioactive whey peptides are thought to act as ACE inhibitors, blocking angiotensin I conversion.

Yarrow extracts demonstrate antihypertensive and vasorelaxant effects in spontaneously hypertensive rat models, mediated by sesquiterpene lactones leucodin and achillin through calcium channel blockade and endothelium-dependent NO/cGMP-dependent pathways. Used traditionally for hypertension in Mexican and European folk medicine.

Clinical studies in type 2 diabetic adults and in elderly hypertensives show that brewer's yeast significantly reduces systolic and diastolic blood pressure. Proposed mechanisms include ACE-inhibiting peptides in yeast and the high content of potassium, magnesium, and calcium. Effects have been replicated across at least two human trials.

Yellow Root contains berberine, for which there is limited but present human clinical data suggesting blood pressure-lowering effects. Two low-quality controlled trials reported improvements in diastolic and/or systolic blood pressure with berberine. A systematic review concluded the evidence is limited and inconclusive. Yellow Root was documented as a southern US folk remedy for high blood pressure.

A 2025 crossover RCT found that 8 weeks of daily yerba mate consumption significantly reduced blood pressure in both healthy adults and those at cardiovascular risk. This effect was observed alongside reductions in inflammatory cytokines and chemokines.

Yohimbine has well-documented, pharmacologically verified effects on blood pressure. At standard oral doses it raises blood pressure in normal volunteers via increased sympathetic outflow and norepinephrine spillover; this effect is significantly greater in hypertensive patients. Conversely, it has been used therapeutically to raise blood pressure in conditions of pathologically low pressure such as neurogenic orthostatic hypotension.

Bingham (1978, J Appl Nutr) reported blood pressure reductions in patients taking yucca saponin tablets, and Rxlist/Drugs.com cite that yucca may reduce hypertension in combination with diet and exercise. Animal studies (L-NAME hypertensive rat model) showed YSE significantly reduced mean arterial blood pressure. Human evidence remains limited to older, less-rigorous reports.

Preclinical evidence supports antihypertensive effects for certain Zanthoxylum species. Aqueous extract of Z. tessmannii (syn. Fagara tessmannii) attenuated L-NAME-induced hypertension in rats by lowering triacylglycerol, total cholesterol, and atherogenic index while protecting kidney, liver, and heart tissues. Human data are absent.

A. spectabilis is documented in Himalayan ethnobotany as a traditional treatment for hypotensive (blood pressure-lowering) conditions. The 2026 Scientific Reports paper records hypotensive use alongside hypoglycemic use in traditional medicine.

Adrenal cortex extract is traditionally used for low blood pressure, particularly within the framework of mineralocorticoid (aldosterone) deficiency. The zona glomerulosa of the adrenal cortex produces aldosterone, which directly regulates sodium retention and blood volume, hence blood pressure. No clinical trial has validated OTC adrenal cortex supplements for blood pressure regulation.

Anemarrhena is used in TCM combinations with Phellodendron and Rehmannia to treat hypertension presenting with Liver-fire deficiency symptoms. Laboratory animal studies confirm blood-pressure-lowering effects, and steroidal saponins from anemarrhena exhibit anti-platelet aggregation activity relevant to cardiovascular health.

In spontaneously hypertensive rats, argan oil reduced mean blood pressure and improved endothelial NO-mediated vasodilation (PMID 15613254). Preclinical glucose-fed rat models also show blood pressure reduction. Human clinical trial data for blood pressure as a primary endpoint are lacking.

Epimedium has a traditional TCM use for hypertension and has been studied in Chinese clinical preparations for high blood pressure. Icariin's vasodilatory and eNOS-upregulating properties provide biological plausibility. Controlled clinical trials specifically for blood pressure as a primary outcome have not been published.

Antihypertensive activity of T. bellirica is documented in traditional Indian medicine and ScienceDirect notes it is used for hypertension. Animal and in vitro studies support vasodilatory and antihypertensive effects, and a polyherbal formulation containing T. bellirica showed blood pressure-lowering effects in a rat hypertension model. No dedicated human RCT on T. bellirica monotherapy for blood pressure has been published.

Traditional Chinese medicine uses boxthorn root bark as a treatment for high blood pressure, and early Chinese clinical use of lycium root for hypertension is documented. Recent research indicates lycium root reduces blood glucose and lipid levels; its vasodilatory properties are noted in TCM ethnopharmacology. Robust controlled human trials specific to blood pressure reduction are not yet published.

Cassia bark is listed in traditional Chinese medicine and folk medicine as a remedy for hypertension, and blood pressure is noted as a traditional use on authoritative databases including RxList. One clinical trial registered on ClinicalTrials.gov included blood pressure as an outcome measure for C. cassia in T2DM, but published clinical evidence specifically for blood pressure effects is currently insufficient to qualify as scientific.

Cowpea is traditionally used for hypertension in African and South Asian folk medicine, documented in ethnobotanical sources. Scientific literature notes antihypertensive potential attributable to bioactive peptides and potassium content, but no dedicated human clinical trial has confirmed this.

Chamomile has been traditionally used for hypertension, and its phytochemicals are noted in pharmacological reviews for antihypertensive activity. Animal model studies show antihypertensive effects. Germany's Commission E acknowledgment and WHO monograph inclusion suggest recognized traditional and pharmacological relevance, though human clinical trials specifically for blood pressure are lacking.

Chickweed's traditional diuretic action is linked by herbalists to potential blood pressure support via fluid and sodium elimination. Anne McIntyre specifically notes its diuretic action may be helpful in hypertension. No clinical evidence exists.

Cleavers has documented traditional use for hypertension in multiple medicine systems, listed as a vasomodulator alongside its diuretic properties. A PMC review notes its use 'in the treatment of various diseases such as diabetes, cancer, and hypertension.' Evidence is preclinical and traditional only.

Dioscorea is listed in traditional Asian medicine for hypertension (PMC4632431), and its cholesterol-lowering and anti-inflammatory properties provide indirect mechanistic relevance. No human studies specifically examining blood pressure effects of Dioscorea have been conducted.

Traditional preparations of dodder have been reported to lower blood pressure in animal models, including a positive inotropic effect on frog heart specimens and antihypertensive effects in anesthetized dogs reported in classical pharmacological literature. The genus is listed as demonstrating antihypertensive activity. Evidence remains at the level of traditional use with animal pharmacology.

Elderberry polyphenols are associated with blood pressure reduction in animal models and epidemiological reviews. Animal studies show S. nigra extract reduces blood pressure in hypertensive models, particularly in combination with antihypertensive agents. The reduction of uric acid levels by elderberry polyphenols is also noted as a related mechanism. Human RCT data are lacking.

Gamma oryzanol is used for high blood pressure in traditional and complementary medicine contexts, and it is listed among its uses on clinical reference sites. However, WebMD and EBSCO note there is no good scientific evidence supporting this use. One animal study in a metabolic syndrome model showed no significant effect on systolic blood pressure.

Swertia chirayita (Gentianaceae) has traditional documented use for lowering blood pressure in Ayurvedic and Himalayan medicine, documented in a PMC review. G. lutea's anti-atherosclerotic preclinical data (eNOS activation, smooth muscle relaxation) offers indirect biological plausibility. No clinical trials on gentian and blood pressure exist.

Goji berry has been used in TCM for over 2,000 years for hypertension and cardiovascular conditions. LBP has documented cardioprotective effects in animal models, and a 2025 review characterizes LBP as used to treat hypertension in traditional Chinese medicine. Dedicated human RCTs for blood pressure outcomes are limited; the evidence base is primarily traditional with supportive preclinical data.

Animal and test-tube studies suggest goldenrod may help lower blood pressure, and antihypertensive activity is listed among its pharmacological activities in a comprehensive PMC review. A 1983 study in rats showed blood pressure-lowering effects of aqueous goldenrod extract. The diuretic action provides indirect antihypertensive rationale. Human clinical evidence is absent.

Reduction of high blood pressure is listed among the traditional medicinal uses of I. aquifolium leaves in multiple folk medicine sources. Other Ilex species with better-studied evidence support cardiovascular/blood pressure effects, providing biological plausibility. No human clinical trials exist for I. aquifolium.

In TCM, honeysuckle is used in combination with Chrysanthemum flowers to lower high blood pressure. Experimental data suggest that flower extracts reduce blood pressure in animal models, and a cardiovascular review documents preclinical evidence for honeysuckle in hypertension management. Human clinical trial data are absent.

Horsetail is traditionally cited for blood pressure support, with its diuretic activity providing the principal proposed mechanism—diuresis lowers circulating blood volume, which can reduce blood pressure. Horsetail's diuretic effect has been confirmed in a small human RCT. No clinical trials have directly measured blood pressure outcomes with horsetail supplementation.

Traditional Indian medicine (Ayurveda and folk medicine) documents bael as a remedy for high blood pressure. Pharmacological properties including vasodilatory effects and antioxidant protection of vasculature provide mechanistic plausibility, but dedicated clinical or preclinical blood pressure studies are limited.

Hypertension is listed as a traditional indication for P. orientalis in systematic reviews, including the IJSDR 2022 systematic review. Korean folk medicine uses the plant as a hypotensor. No human clinical trial data for blood pressure endpoints have been identified.

Posterior pituitary extract has a historical clinical application related to blood pressure via ADH (vasopressin), which at high concentrations increases peripheral vascular resistance. Injected posterior pituitary extract was used clinically in the early 20th century. Oral supplementation for blood pressure support is a traditional extension without modern clinical evidence.

Hypertension and hypotension are both listed as traditional indications for rehmannia in established monographs. Preclinical pharmacological reviews document cardiovascular system actions, and TCM hypertension formulas commonly include rehmannia. Human clinical trial data for isolated rehmannia on blood pressure are lacking.

Shepherd's purse contains rutin, choline, and acetylcholine — identified as hypotensive compounds — and is traditionally used in European herbal medicine for mild high blood pressure. Pharmacological studies confirm vasoconstrictor and blood-pressure-modulating effects, but clinical human trials confirming antihypertensive efficacy are absent.

S. baicalensis (Huang Qin) is applied clinically in China for hypertension and is historically prescribed for high blood pressure in TCM. Baicalin has demonstrated antihypertensive effects in preclinical cardiovascular research. Baicalin is involved in clinical trials for antihypertensive effects per ScienceDirect review 2023.

Solomon's seal has a traditional and contemporary herbal use for supporting healthy blood pressure, cited in TCM formulations and by Western herbalists. However, Drugs.com and caringsunshine.com note this use is based mainly on tradition and anecdote, without robust clinical evidence.

Swertia chirayita is documented in multiple traditional medicine sources and pharmacological reviews as having hypotensive (blood pressure-lowering) activity. Research investigations have indicated that plant formulations can regulate blood pressure. Formal clinical trial evidence is not available.

Thymol and carvacrol from T. vulgaris have demonstrated antihypertensive and vasorelaxant effects in preclinical animal models, attributed to calcium channel blocking activity in vascular smooth muscle. A Frontiers in Pharmacology study (2025) confirmed thymol-rich T. vulgaris EO significantly lowered blood pressure in hypertensive animal models. Human clinical evidence is absent.

Traditional use of Tongkat Ali taproots specifically for treating high blood pressure is documented in Southeast Asian ethnobotanical records. The NIH-referenced PMC review explicitly states the taproots are used to treat high blood pressure in folk medicine. A formal document from the Office of the Pentagon Supplement Safety (OPSS) also notes traditional use to reduce blood pressure. No human clinical trials have assessed blood pressure as a primary outcome.

Tribulus has been used traditionally in Ayurveda and TCM for hypertension. Animal studies show ACE inhibition and NO-mediated smooth muscle relaxation lower blood pressure in hypertensive rats. Human clinical trial data are absent; WebMD notes mixed results and possible confounding from supplement contaminants.

Triphala is mentioned in Ayurvedic tradition as a cardiovascular tonic that strengthens capillaries and improves circulation, effects that could indirectly support blood pressure regulation. Preclinical evidence supports lipid-lowering and vascular protective effects. No human RCT has specifically measured blood pressure as a primary endpoint.

Watercress is documented as a traditional remedy for hypertension across multiple cultures including Iranian, Moroccan, and broader traditional medicine systems. It is also a natural source of dietary nitrates, which have a well-established vasodilatory mechanism. A 2025 RCT pilot study examined watercress for cardiovascular risk factors including blood pressure in Thai adults.

Wheatgrass is documented in traditional folk medicine and naturopathic practice for blood pressure reduction. Preclinical and review sources suggest vasodilatory potential from chlorophyll and potassium/magnesium content. Human clinical evidence for antihypertensive effects specifically is minimal and underpowered.

Wild yam has been described in traditional herbalism as a vasodilator and cardiac sedative with hypotensive potential. Russian and traditional Chinese herbal medicine systems classify it as a vasodilator. The Komesaroff et al. (2001) RCT found no effect on blood pressure after 3 months of topical wild yam cream. Animal studies on dioscorin from related Dioscorea species showed hypotensive effects.

Wood betony glycosides have been reported to demonstrate hypotensive activity by unblocking constrictive blood vessels in pharmacological research cited in the peer-reviewed phytochemical literature. Russian researchers documented hypotensive principals. Use in hypertension is traditional/clinical-herbalist practice without human RCT data.